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on laboratory and clinical monitoring and on rever-
sal strategies. 
 More recently, new oral anticoagulant drugs, namely 
the direct thrombin inhibitor dabigatran etexilate and 
the direct factor Xa inhibitor rivaroxaban, have been 
approved for clinical use in several countries. A growing 
body of laboratory and clinical data is becoming avail-
able to better understand the mechanisms of action and 
the optimal management of these new compounds. In 
this article we summarize the published literature con-
cerning the pharmacokinetics and pharmacodynamics 
of all oral anticoagulant drugs that are currently avail-
able for clinical use and other aspects related to their 
management. 
 For many decades, the vitamin K antagonists (VKAs) have been the only oral anticoagulant 
drugs available for clinical use for the primary and 
secondary prevention of venous and arterial throm-
boembolic events. VKAs have been consistently 
shown to be highly effective in many settings and 
are now used by millions of patients worldwide. 
Laboratory and clinical studies have contributed to 
understanding of the complex pharmacokinetics 
and pharmacodynamics of VKAs, their interac-
tions, antithrombotic effects, and the risks associ-
ated with their use. Several studies have addressed 
the practical issues related to the management of 
patients on VKAs treatment, with particular focus 
 Background:  The objective of this article is to summarize the published literature concerning the 
pharmacokinetics and pharmacodynamics of oral anticoagulant drugs that are currently available 
for clinical use and other aspects related to their management. 
 Methods:  We carried out a standard review of published articles focusing on the laboratory and 
clinical characteristics of the vitamin K antagonists; the direct thrombin inhibitor, dabigatran 
etexilate; and the direct factor Xa inhibitor, rivaroxaban. 
 Results:  The antithrombotic effect of each oral anticoagulant drug, the interactions, and the mon-
itoring of anticoagulation intensity are described in detail and discussed without providing spe-
cifi c recommendations. Moreover, we describe and discuss the clinical applications and optimal 
dosages of oral anticoagulant therapies, practical issues related to their initiation and monitoring, 
adverse events such as bleeding and other potential side effects, and available strategies for 
reversal. 
 Conclusions:  There is a large amount of evidence on laboratory and clinical characteristics of 
vitamin K antagonists. A growing body of evidence is becoming available on the fi rst new oral 
anticoagulant drugs available for clinical use, dabigatran and rivaroxaban. 
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effect of the VKAs can be overcome by low doses of 
phytonadione (vitamin K) ( Fig 1 ). 
 1.2 Pharmacokinetics and Pharmacodynamics 
 Warfarin is a racemic mixture of two optically 
active isomers, the R and S enantiomers. Warfarin is 
highly water soluble, is rapidly absorbed from the 
gastrointestinal tract, has high bioavailability, 15,16 and 
reaches maximal blood concentrations about 90 min 
after oral administration. 15,17 Racemic warfarin has a 
half-life of 36 to 42 h 18 (R-warfarin 45 h, S-warfarin 
29 h), circulates bound to plasma proteins (mainly 
albumin), and accumulates in the liver where the two 
enantiomers are metabolically transformed by dif-
ferent pathways ( Fig 1 ). 18 The S enantiomer of warfa-
rin (2.7-3.8 times more potent than the R enantiomer) 
undergoes approximately 90% oxidative metabolism, 
primarily by the CYP2C9 enzyme of the cytochrome 
P450 system and to a lesser extent by CYP3A4. 19 The 
less potent R enantiomer undergoes approximately 
60% oxidative metabolism, primarily by two cyto-
chrome P450 enzymes, CYP1A2 and CYP3A4, and to 
a lesser extent by CYP2C19. The remainder of the 
metabolism of both enantiomers involves reduction 
to diastereomeric alcohols. The relationship between 
the dose of warfarin and the response is modifi ed by 
genetic and environmental factors that can infl uence 
the absorption of warfarin, its pharmacokinetics, and 
its pharmacodynamics. 
 Other available VKAs include acenocoumarol, phen-
procoumon, and fl uindione. Like warfarin, aceno-
coumarol and phenprocoumon also exist as optical 
isomers, but with different stereochemical character-
istics. R-acenocoumarol has an elimination half-life 
of 9 h, is primarily metabolized by CYP2C9 and 
CYP2C19, and is more potent than S-acenocoumarol 
because of faster clearance of S-acenocoumarol, 
which has an elimination half-life of 0.5 h and is pri-
marily metabolized by CYP2C9. 20 Phenprocoumon is 
a much longer-acting agent, with both the R- and 
S-isomers having elimination half-lives of 5.5 days. Both 
are metabolized by CYP2C9, and S-phenprocoumon 
is 1.5 to 2.5 times more potent than R-phenprocou-
mon. 21 Finally, fl uindione is an indandione VKA with 
a mean half-life of 31 h. 22 Unlike warfarin, fl uindione 
is not a chiral compound. 22 
 1.3 Interactions 
 1.3.1 Genetic Factors:  A number of point muta-
tions in the gene coding for the CYP2C9 have been 
identifi ed. 23 These polymorphisms, the most common 
of which are CYP2C9*2 and CYP2C9*3, are associ-
ated with an impaired ability to metabolize S-warfarin, 
resulting in a reduction in S-warfarin clearance and, 
 1.0 Vitamin K Antagonists 
 1.1 Pharmacology 
 VKAs produce their anticoagulant effect by inter-
fering with the cyclic interconversion of vitamin K 
and its 2,3 epoxide (vitamin K epoxide), thereby 
modulating the  g -carboxylation of glutamate residues 
(Gla) on the N-terminal regions of vitamin K-dependent 
proteins ( Fig 1 ). 1-8 The vitamin K-dependent coagula-
tion factors II, VII, IX, and X require  g -carboxylation 
for their procoagulant activity, and treatment with 
VKAs results in the hepatic production of partially 
carboxylated and decarboxylated proteins with reduced 
coagulant activity. 9,10 Carboxylation is required for a 
calcium-dependent conformational change in coagu-
lation proteins 11-13 that promotes binding to cofactors 
on phospholipid surfaces. In addition, the VKAs 
inhibit carboxylation of the regulatory anticoagulant 
proteins C, S, and Z and thereby have the potential to 
be procoagulant. 14 Although the anticoagulant effect 
of VKAs is dominant, a transient procoagulant effect 
may occur when baseline protein C and protein S 
levels are reduced due to the start of VKA therapy 
and the acute phase of a thrombotic event and before 
the balanced decrease of vitamin K-dependent clot-
ting factor levels is achieved. Carboxylation requires 
the reduced form of vitamin K (vitamin KH 2 ), a 
 g -glutamyl carboxylase, molecular oxygen, and CO 2 . 1 
Vitamin K epoxide can be reused by reduction to 
VKH 2 . The oxidation-reduction reaction involves a 
reductase pair. The fi rst, vitamin K epoxide reduc-
tase, is sensitive to VKA, whereas vitamin K reduc-
tase is less sensitive. 1-3 Therefore, the anticoagulant 
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(VKOR) enzyme fi rst described in 1974. 36 The gene 
coding for the VKOR protein is located on the short 
arm of chromosome 16. 37,38 The gene encodes for 
several isoforms of a protein that are collectively 
termed the vitamin K oxide reductase complex 1 
(VKORC1). Subsequently, mutations in this gene 
have been identifi ed leading to enzymes with vary-
ing sensitivities to inhibition by warfarin, 38-43 thereby 
affecting the pharmacodynamics of warfarin. The 
mutations occur with differing frequencies in various 
ethnic populations and account, in part, for the dif-
ference in warfarin doses required to maintain a ther-
apeutic international normalized ratio (INR) (Table 
S1) (tables that contain an “S” before the number 
denote supplementary tables not contained in the 
body of the article and available instead in an online 
data supplement; see the “Acknowledgments” for 
more information). 39-41,44,45 
 Genetic mutations in the gene coding for the 
VKORC1often involve several mutations leading to 
various haplotypes that cause greater resistance to 
warfarin therapy. Harrington et al 43 found a warfarin-
resistant individual who had high serum warfarin 
as a result, an increased S-warfarin elimination half-
life. 24 Mutations in this gene occur with different 
frequencies in various ethnic groups (Table S1). 25,26 
In comparison with patients who are homozygous 
for the wild-type allele (CYP2C9*1*1), patients 
with heterozygous (CYP2C9*1*2, CYP2C9*1*3, 
CYP2C9*2*3) or homozygous (CYP2C9*2*2, 
CYP2C9*3*3) expression of a variant allele require 
lower doses of warfarin, as determined by a systematic 
review of the literature and meta-analysis of studies 
that assessed the infl uence of CYP2C9 polymor-
phisms on warfarin dose requirements (Table S2). 27 
Several investigations 25,28,29 have shown that these 
mutations, as well as others, 30-32 are also associated 
with an increase in bleeding complications associated 
with warfarin therapy. Mutations in CYP2C9 also 
affect acenocoumarol, although to a lesser degree 
because the anticoagulation potencies of the R and S 
enantiomers are comparable. 33,34 The effects of CYP2C9 
polymorphisms are least pronounced with the use of 
phenprocoumon. 33,35 
 The target for warfarin’s inhibitory effect on the 
vitamin K cycle is the vitamin K oxide reductase 
 Figure 1. [Section 1.1] Vitamin K 1 is reduced to vitamin KH2. The major warfarin-sensitive enzyme in 
this reaction is the vitamin K oxide reductase mainly inhibited by the S-enantiomer of warfarin. S-warfarin 
is metabolized by the p450 cytochrome enzyme, CYP2C9. Reprinted with permission from Ansell et al. 8 
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tive metabolism of either the S-enantiomer or 
R-enantiomer of warfarin). The inhibition of S-warfarin 
metabolism is more important clinically, because this 
enantiomer is more potent than the R-enantiomer as 
a VKA. 50,51 Phenylbutazone, 52 sulfi npyrazone, 53 metro-
nidazole, 54 and trimethoprimsulfamethoxazole 55 inhibit 
the clearance of S-warfarin, and each potentiates the 
effect of warfarin on the prothrombin time (PT). In 
contrast, drugs such as cimetidine and omeprazole, 
which inhibit the clearance of the R-isomer, poten-
tiate the PT only modestly in patients who are treated 
with warfarin. 51,54,56 Amiodarone is a potent inhibitor 
of the metabolic clearance of both the S-enantiomer 
and the R-enantiomer and potentiates warfarin anti-
coagulation. 57 The anticoagulant effect of warfarin is 
inhibited by drugs like barbiturates, rifampin, azathi-
oprine, and carbamazepine, which increase its clear-
ance by inducing hepatic metabolism. 58 Azathioprine 
also reduces the anticoagulant effect of warfarin, pre-
sumably through a potentiating effect on hepatic 
clearance. 59 Long-term alcohol consumption has a 
similar potential to increase the clearance of warfarin, 
but ingestion of even relatively large amounts of wine 
had little infl uence on the PT in normal volunteers 
who were given warfarin. 60 The effect of enzyme 
induction on warfarin therapy has been analyzed in 
a critical review. 58 Ten hepatic microsomal enzyme 
agents were assessed. Enzyme induction of warfarin 
metabolism by rifampin and barbiturates was consid-
ered likely, and an interaction with carbamazepine, 
griseofulvin, aminoglutethimide, nafcillin, and diclox-
acillin was considered probable. 
 Drugs may also infl uence the pharmacodynamics 
of warfarin by inhibiting the synthesis of or increas-
ing the clearance of vitamin K-dependent coagula-
tion factors or by interfering with other pathways of 
hemostasis. The anticoagulant effect of warfarin is aug-
mented by second-generation and third-generation 
cephalosporins, which inhibit the cyclic interconver-
sion of vitamin K; 61,62 by thyroxine, which increases the 
metabolism of coagulation factors; 63 and by clofi brate 
through an unknown mechanism. 64 Doses of salicylates 
of  . 1.5 g per day 65 may augment the anticoagulant 
effect of warfarin. Acetaminophen potentiates the 
effect of warfarin when used over prolonged periods 
of time, as demonstrated in a recent randomized, 
blinded trial. 66-68 Acetaminophen possibly potentiates 
the anticoagulant effect of warfarin through inhibi-
tion of VKOR by a toxic metabolite of the drug, 69 
although the accumulation of this metabolite may 
vary among individuals, thus accounting for a variable 
potentiating effect. 70 Heparin potentiates the anti-
coagulant effect of warfarin, but in therapeutic doses 
produces only a slight prolongation of the PT. The 
mechanisms by which erythromycin 71 and some ana-
bolic steroids 72 potentiate the anticoagulant effect of 
concentrations and a 196G . A transition, predicting 
a Val66Met substitution in VKORC1. D’Andrea et al, 39 
studying 147 patients, found that those with a 1173CC 
genotype required a higher mean maintenance dose 
compared with those with a CT or TT genotype, as did 
Quiteineh et al, 46 who found that a 1173 C . T poly-
morphism was signifi cantly associated with the risk 
of anticoagulant overdose. By identifying a number 
of noncoding single nucleotide polymorphisms, 
Rieder et al 40 were able to infer that there are fi ve 
major haplotypes associated with different dose 
requirements for maintaining a therapeutic INR. 
The maintenance dose ranged from a low of 2.7 mg 
warfarin per day for the sensitive haplotypes up to 
a high of 6.2 mg per day for the resistant haplo-
types. Asian Americans had the highest proportion 
of sensitive haplotypes, whereas African Americans 
more frequently exhibited the resistant haplotypes 
(Table S1). 
 1.3.2 Drugs:  VKAs are highly susceptible to 
drug-drug interactions. For warfarin, for example, 
manufacturer-provided product information lists  . 200 
specifi c agents that may interfere with this agent. 47 
Unfortunately, there seems to be little concordance 
among commonly used drug compendia and product 
labels with respect to interactions involving warfarin. 
Indeed, a major problem with the literature on this 
topic is that many reports are single-case reports and 
are not well documented. Anthony et al 44 recently 
reviewed three drug information compendia, Clinical 
Pharmacology, ePocrates, and Micromedex, and the 
warfarin sodium (Coumadin) product label approved 
by the US Food and Drug Administration, for listings 
of interactions between warfarin and drugs, biologics, 
foods, and dietary supplements and found that of 
a total of 648 entries from the four sources, only 50 
were common to all the sources. 44 As in the previous 
edition of this article, 8  Table 1 summarizes a compre-
hensive list of drugs that potentiate, inhibit, or have 
no effect on the anticoagulant effect of warfarin based 
on the results of a systematic review of available evi-
dence completed in 2005, which rated warfarin drug 
interaction reports according to interaction direc-
tion, clinical severity, and quality of evidence, and 
developed lists of warfarin drug interactions consid-
ered highly probable, probable, possible, and highly 
improbable. 48 
 Drugs such as cholestyramine can reduce the anti-
coagulant effect of warfarin by reducing its absorp-
tion. Other drugs potentiate the anticoagulant effect 
of warfarin by inhibiting its clearance, whereas 
some drugs may inhibit the anticoagulant effect by 
enhancing its clearance. 49 These latter effects may be 
through stereoselective or nonselective pathways, 50,51 
(stereoselective interactions may affect the oxida-
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warfarin are unknown. Sulfonamides and several broad-
spectrum antibiotic compounds may augment the anti-
coagulant effect of warfarin in patients consuming 
diets that are defi cient in vitamin K by eliminating bac-
terial fl ora and aggravating vitamin K defi ciency. 73 
 Drugs such as aspirin, 74 nonsteroidal antiinfl am-
matory drugs, 75,76 penicillins in high doses, 77,78 and 
moxalactam 62 increase the risk of warfarin-associated 
bleeding by inhibiting platelet function. Of these, aspi-
rin is the most important because of its widespread 
use and prolonged effect. 79,80 Aspirin and nonsteroidal 
antiinfl ammatory drugs can also produce gastric ero-
sions that increase the risk of upper GI bleeding. This 
can occur even with COX-2 inhibitors, which were 
originally believed to be less likely to predispose to 
gastric bleeding than nonsteroidal antiinfl ammatory 
drugs. 76 In one case-controlled analysis of 98,821 sub-
jects on warfarin identifi ed in linked databases, cele-
coxib and rofecoxib were associated with a 1.7- or 
2.4-fold increased risk of GI hemorrhage, respec-
tively. 76 The risk of clinically important bleeding is 
heightened when high doses of aspirin are taken dur-
ing high-intensity warfarin therapy (INR, 3.0-4.5). 74,81 
However, low doses of aspirin (ie, 75 to 100 mg daily) 
combined with moderate-intensity and low-intensity 
warfarin anticoagulation therapy are also associated 
with increased rates of bleeding. 82,83 The effect of sta-
tins or fi brates on the risk of bleeding in patients on 
VKAs is controversial. The initiation of a fi brate or 
statin that inhibits CYP3A4 enzymes was recently 
reported to increase the risk of gastrointestinal bleed-
ing in warfarin-treated patients, whereas other statins 
that are mainly excreted unchanged were not found 
to be associated with such an increased risk. 84 Con-
versely, other authors reported that long-term statin 
use is associated with a decreased risk of bleeding 
complications in patients with atrial fi brillation (AF) 
on warfarin therapy. 85 
 The most effective method to avoid adverse out-
comes associated with drug interactions is to try to 
avoid, when feasible, concurrent use of potentially 
interacting drugs and to use noninteracting alterna-
tives instead. When noninteracting alternatives are 
not available, adverse outcomes can be avoided by 
increasing the frequency of monitoring and adjusting 
warfarin doses based on INR response. Prospective 
dosing adjustments are inappropriate because of the 
unpredictable nature of patient response to drug 
interactions (see Holbrook et al 86 in this supplement ). 
 1.3.3 Environmental Factors:  Nutritional supple-
ments and herbal products are particularly problem-
atic in that warfarin-treated patients often fail to inform 
physicians that they are using such products and 
physicians rarely ask. In one survey of 1,200 patients 
from four large anticoagulation clinics (ACs) in the 
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of coagulation factors. 104 These patients may appear 
to be “auto-anticoagulated” with baseline elevated 
INRs, but the degree of suppression of clotting fac-
tors does not mimic that of patients treated with 
warfarin and is not suffi cient to prevent thromboem-
bolism. 105 Hypermetabolic states produced by fever 
or hyperthyroidism increase warfarin responsiveness, 
probably by increasing the catabolism of vitamin 
K-dependent coagulation factors. 70,106 Certain com-
ponents of cigarette smoke may induce CYP1A2, and 
warfarin dosing requirements have been observed 
to decline after smoking cessation. 107,108 Chewing 
tobacco contains high quantities of vitamin K that 
can increase warfarin dose requirements. 109 Exacer-
bations of heart failure can increase responsiveness 
to warfarin therapy, likely in response to the effect of 
hepatic congestion on warfarin metabolism. 110 End-
stage renal disease is associated with reduced activity of 
CYP2C9, leading to lower warfarin dosing require-
ments in these patients. 111 Warfarin dosing require-
ments decline with advanced age as a result of reduced 
availability of vitamin K stores and lower plasma concen-
trations of vitamin K-dependent clotting factors. 112-114 
In fact, age may be the single most important easily 
obtained predictor of warfarin dosing requirement. 115 
 1.4 Antithrombotic Effect 
 The antithrombotic effect of VKAs is attributed 
to their anticoagulant effect, which in turn is medi-
ated by the reduction of four vitamin K-dependent 
coagulation factors. The experiments of Wessler and 
Gitel 116  . 40 years ago using a stasis model of throm-
bosis in rabbits showed that the antithrombotic effect 
of warfarin requires 6 days of treatment and requires 
the reduction of prothrombin (factor II), which has a 
relatively long half-life of about 60 to 72 h, compared 
with 6 to 24 h for other vitamin K-dependent factors. 
In a rabbit model of tissue factor-induced intravas-
cular coagulation, the protective effect of warfarin 
mainly resulted from lowering prothrombin levels. 117 
Patel and associates 118 demonstrated that clots formed 
from umbilical cord plasma containing about half the 
prothrombin concentration of plasma from adult 
control subjects generated signifi cantly less fi brino-
peptide A than clots formed from maternal plasma. 
The view that warfarin exerts its antithrombotic 
effect by reducing prothrombin levels is consistent 
with observations that clot-bound thrombin is an 
important mediator of clot growth 119 and that reduc-
tion in prothrombin levels decreases the amount of 
thrombin generated and bound to fi brin, thereby 
reducing thrombogenicity. 118 
 The suggestion that the antithrombotic effect of 
VKAs is refl ected in lower levels of prothrombin 
forms the basis for overlapping the administration of 
United States, one-third of the patients used dietary 
supplements and one-third of all patients surveyed 
indicated that their provider failed to discuss potential 
interactions with them. 87 There is also little or no 
standardization of the content of such products, espe-
cially herbal remedies, and reports of interactions 
are often anecdotal or single-case reports, without 
good substantiation. 88-91 Of the higher-quality studies, 
ginkgo and ginger were shown not to have an effect 
on the pharmacokinetics and pharmacodynamics of 
warfarin in healthy subjects in a randomized, open-
label, crossover, study, 92 and coenzyme Q 10 (and ginkgo) 
was shown not to have an effect on warfarin dosage in 
a randomized, double-blind, crossover study. 93 Ginseng 
was shown to reduce the effect of warfarin in a ran-
domized, placebo-controlled trial. 94 Not surprisingly, 
products such as green tea, with a high content of 
vitamin K, were shown to reduce the anticoagulant 
effect of warfarin. 48 
 Subjects receiving long-term warfarin therapy are 
sensitive to fl uctuating levels of dietary vitamin K, 95,96 
which is derived predominantly from phylloquinones 
in plant material. 96 Sadowski and associates 97 have 
listed the phylloquinone content of a wide range of 
food, and the list can be found on the Internet (http://
ods.od.nih.gov/factsheets/cc/coumadin1.pdf). Phyllo-
quinones act through the warfarin-insensitive path-
way. 98 Important fl uctuations in vitamin K intake 
can occur in both healthy and sick subjects. 99 An 
increased intake of dietary vitamin K that is suffi -
cient to reduce the anticoagulant response to warfa-
rin occurs in patients consuming green vegetables or 
vitamin K-containing supplements, during weight-
reduction diets, and in patients who have been treated 
with vitamin K supplements. 100 Reduced dietary 
vitamin K intake potentiates the effect of warfarin in 
ill patients who have been treated with antibiotics 
and IV fl uids without vitamin K supplementation and 
in patients who have states of fat malabsorption. 
 In general, a consistent intake of vitamin K-
containing foods is advisable, but neither specifi c 
restrictions nor additions seem necessary in patients 
with stable anticoagulant control. Patients should be 
informed of possible changes in INR, in particular in 
response to the use of dietary supplements or herbs, 
or alcohol used chronically or ingested in large 
quantities. 101,102 More frequent monitoring of the INR 
should be proposed if dietary habits have substan-
tially changed in response to weight reduction diets, 
periods following hospitalization, treatment with 
chemotherapy, sustained diarrhea or vomiting, or in 
case of anorexia. 103 
 A number of other conditions and disease states 
have been observed to infl uence anticoagulation 
with warfarin. Hepatic dysfunction potentiates the 
response to warfarin through the impaired synthesis 
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normal plasma. A calibration model, 121 which was 
adopted in 1982, is now used to standardize reporting 
by converting the PT ratio measured with the local 
thromboplastin into an INR, calculated as follows:
 INR  5 (patient PT/mean normal PT) ISI 
or
 log INR  5 ISI(log observed PT ratio) 
where ISI denotes the ISI of the thromboplastin 
used at the local laboratory to perform the PT mea-
surement. The ISI refl ects the responsiveness of a 
given thromboplastin to the reduction of the vitamin 
K-dependent coagulation factors compared with the 
primary World Health Organization (WHO) inter-
national reference preparations, so that the more 
responsive the reagent, the lower the ISI value. 121 
It is proposed that patients’ samples for calibration 
should be selected by rejecting samples beyond the 
1.5 to 4.5 INR range. 122 Outliers, defi ned as points 
with a perpendicular distance greater than three 
residual SDs from the line of relationship, should be 
rejected. Selection of patients’ samples and rejec-
tion of outliers results in a reduction of the between-
laboratory variation of calibration. 122 
 As the INR standard of reporting was widely 
adopted, a number of problems surfaced. These are 
listed in  Table 2 and are reviewed briefl y here. 
 The INR is based on ISI values derived from the 
plasma of patients who had received stable antico-
agulant doses for at least 6 weeks. 123 As a result, 
the INR has not been validated and should be viewed 
with some skepticism early in the course of warfarin 
therapy, particularly when results are obtained from 
different laboratories. Even under these conditions, 
a parenteral anticoagulant with warfarin until the PT 
or INR is prolonged into the therapeutic range 
during the treatment of patients with thrombosis. 
Since the half-life of prothrombin is about 60 to 
72 h, at least 5 days of overlap is necessary. 
 1.5 Monitoring Anticoagulant Intensity: the INR 
 The PT test 120 is the most common test used to 
monitor VKA therapy. The PT responds to a reduc-
tion of three of the four vitamin K-dependent proco-
agulant clotting factors (ie, II, VII, and X) that are 
reduced by warfarin at a rate proportional to their 
respective half-lives. Thus during the fi rst few days 
of warfarin therapy the PT refl ects mainly a reduc-
tion of factor VII, the half-life of which is approxi-
mately 6 h. Subsequently, the reduction of factors X 
and II contributes to prolongation of the PT. The 
PT assay is performed by adding calcium and throm-
boplastin to citrated plasma. Thromboplastins vary 
in responsiveness to a reduction of the vitamin 
K-dependent coagulation factors. An unresponsive 
thromboplastin produces less prolongation of the PT 
for a given reduction in vitamin K-dependent clotting 
factors than a responsive one. The responsiveness 
of a thromboplastin can be measured by assessing its 
international sensitivity index (ISI) (see later discus-
sion in this section ). Highly sensitive thromboplastins 
(indicated by an ISI of approximately 1.0) are now 
available that are composed of human tissue factor 
produced by recombinant technology and defi ned 
phospholipid preparations. 
 PT monitoring of VKA treatment is not standard-
ized when expressed in seconds, or as a simple ratio 
of the patient plasma value to that of plasma from a 
healthy control subject, or as a percentage of diluted 
 Table 2— [Section 1.5] Potential Problems With the INR (Causes of Erroneous INR) 8 
Problems Description
1. Incorrect PTR from erroneous PT determination due to 
 Pretest variables (sampling and blood collection problems) Trisodium-citrate concentration, storage time, storage temperature, evacuated 
tube effects, inadequate sample, variations in manual technique
 Incorrect normal value From nonuse of MNPT, error in MNPT due to unrepresentative selection, 
technical faults (see above), nonuse of geometric mean
2. Incorrect ISI of local thromboplastin reagent/test system 
  from lack of reliability of the ISI result provided by the 
manufacturer
Incorrect choice of IRP, poor distribution of coumarin test samples across 
treatment range, inadequate numbers of test samples in ISI calibration, 
incorrect transformation of PTR of test plasmas to INR
3. Drift of ISI since original calibration
4. Instrument (coagulometer) effects on INR at local site
5. Lupus anticoagulant effects on some thromboplastin reagents
6. Lack of reliability of the INR system when used at the onset 
  of warfarin therapy and for screening for a coagulopathy 
in patients with liver disease
7. Relative lack of reliability of INR  . 4.5 as these values 
 excluded from ISI calibrations
INR  5 international normalized ratio; IRP  5 international reference preparation; ISI  5 international sensitivity index; MNPT  5 mean normal 
prothrombin time; PT  5 prothrombin time; PTR  5 prothrombin time ratio.
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are effective, 143,145,146 with individual responses varying 
according to the inpatient or outpatient status, age, 
concomitant treatments, and comorbidities. Thus, 
starting doses of   5 mg might be appropriate in 
the elderly, in patients with impaired nutrition, liver 
disease, or congestive heart failure, and in patients 
who are at high risk of bleeding. 112,115,147,148 An initial 
dose of 2 to 3 mg seems to be appropriate for patients 
who have undergone heart valve replacement, given 
their higher sensitivity to VKAs probably caused by 
the effects of cardiopulmonary bypass and concomi-
tant therapies. 149 Recommendations are provided in 
Holbrook et al. 86 
 As described in section 1.2.1, CYP2C9 genotype 
and VKORC1 haplotype infl uence warfarin dosing 
requirements. In response to these observations, 
numerous investigators have attempted to assess the 
combined infl uence of patient factors on warfarin dos-
ing requirement, with a goal of developing models to 
predict warfarin dose requirements based on assess-
ment of various environmental and genetic factors. 
 Sconce et al 42 found that a combination of CYP2C9 
and VKORC1 genotypes plus height produced the 
best predictive model for estimating warfarin dose, 
whereas Vecsler et al 150 reported that CYP2C9 and 
VKORC1 genotypes together with age and body 
weight could explain as much as 63% of the dose var-
iance, and Herman et al 151 could attribute 60% of 
dose variability to CYP2C9 and VKORC1polymor-
phisms, age, and body surface area. Limdi et al 152 
found that CYP2C9 and VKORC1 polymorphisms 
accounted for 30% of the variability in warfarin dose 
among European Americans but only for 10% among 
African Americans. In a prospective cohort study of 
48 consecutive patients starting warfarin for pos-
torthopedic surgery prophylaxis, the patients with a 
variant CYP2C9 allele had a greater than fourfold 
increase in the risk of the INR exceeding 4.0. How-
ever, this substantial increase in the risk of suprather-
apeutic INR was observed despite the fact that all 
patients had their warfarin dose selected using a com-
plex algorithm that considered CYP2C9 genotype. 153 
 Gage et al 154 developed a dosing algorithm based 
on CYP2C9 and VKORC1 polymorphisms along 
with clinical and demographic factors. In the deriva-
tion cohort of 1,015 patients on warfarin therapy, 
body surface area, age, target INR, amiodarone use, 
smoker status, race, current thrombosis, VKORC1 
polymorphism 1639/3673 G . A, CYP2C9(*)3, and 
CYP2C9(*)2 were all independent predictors of 
warfarin therapeutic dose. 
 Three prospective studies have compared the time 
in therapeutic range (TTR; see section 1.6.2 “Evalu-
ating the Quality of Monitoring: TTR” ) of patients 
using a pharmacogenetics-based dosing strategy 
with the TTR achieved when patients were managed 
however, the INR is more reliable than the uncon-
verted PT ratio, 124 and its use is thus recommended 
during both the initiation and maintenance of VKAs. 
 The validity of the INR in other conditions of 
impaired coagulation has been less frequently evalu-
ated. Some authors have recently challenged the use 
of the INR in patients with liver disease and in par-
ticular in prognostic scores such as the Model for 
End-stage Liver Disease. 125,126 Thus, a new INR spe-
cifi c for liver diseases has been proposed, derived by 
using plasma from patients with liver diseases to cali-
brate thromboplastins instead of plasma from patients 
on oral anticoagulant treatment with VKAs. 125,126 
 The accuracy of the INR can be infl uenced by 
reagents with different sensitivities 127 and also by the 
automated clot detectors now used in most labo-
ratories. 128-135 In general, the College of American 
Pathologists has recommended 136 that laboratories 
should use thromboplastin reagents that are at least 
moderately responsive (ie, ISI  , 1.7) and reagent/instru-
ment combinations for which the ISI has been estab-
lished and validated. 
 ISI values provided by the manufacturers of throm-
boplastin reagents are not invariably correct when 
applied locally, 137-139 and this adversely affects the 
reliability of measurements. Local calibrations can be 
performed using plasma samples with certifi ed PT 
values to determine the instrument-specifi c ISI. The 
mean normal plasma PT is not interchangeable with 
a laboratory control PT. 140 Therefore, the use of other 
than a properly defi ned mean normal PT can yield 
erroneous INR calculations, particularly when less-
responsive reagents are used. The mean normal PT 
should be determined for each new batch of thrombo-
plastin with the same instrument used to assay the PT. 140 
 The concentration of citrate that is used to antico-
agulate plasma may affect the INR. 141,142 In general, 
higher citrate concentrations (eg, 3.8%) lead to higher 
INR values, 141 and underfi lling the blood collection 
tube spuriously prolongs the PT because excess 
citrate is present. Using collection tubes containing 
3.2% concentrations of citrate for blood coagulation 
studies and adequately fi lling tubes can reduce this 
problem. 
 1.6 Practical Issues Related to Initiation 
and Maintenance 
 1.6.1 Approaches to the Induction of VKAs: 
 Following the administration of VKAs, an initial 
effect on the INR usually occurs within the fi rst 2 or 
3 days, depending on the dose administered, and an 
antithrombotic effect occurs within the next several 
days. 143,144 There is room for fl exibility in selecting a 
starting dose of warfarin. The results of clinical studies 
suggest that initiation doses between 5 and 10 mg 
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 1.6.2 Evaluating the Quality of Monitoring: TTR: 
 The relationship between the intensity of treatment 
and the risk of an adverse event has been evaluated 
by examining the frequency of such events as a func-
tion of the TTR. 161-163 A strong relationship between 
TTR and the rates of bleeding or thromboembolic 
events has been observed across studies 161-173 with dif-
ferent patient populations, different target ranges, 
different scales for measuring intensity of anticoagu-
lation (ie, PT, PT ratio, and INR), different methods 
of measuring TTR, and different models of dose man-
agement. In a large, retrospective analysis of patients 
with mechanical heart valves, Cannegieter et al 164 
found that risks of major bleeding or thromboembo-
lism were greatly increased during the times when 
patients were above or below the therapeutic range 
of INR compared with times when they were within 
range. A similar relationship has been demonstrated 
for other groups of patients. 169,174 A recent substudy 
examined the infl uence of TTR on the relative effec-
tiveness of warfarin and dual antiplatelet therapy 
with aspirin plus clopidogrel in patients with nonval-
vular AF, in which the overall result favored warfa-
rin. 165 In this large retrospective analysis, the TTR 
during warfarin therapy appeared to be a major deter-
minant of its effi cacy, since the advantage of warfarin 
over antiplatelet therapy was lost below a threshold 
TTR of between 58% and 65%. 165 The percentage of 
INRs or TTR is highly dependent on the quality of 
dose management as refl ected in studies that report 
TTR. Poor quality of dose management results in a 
high proportion of low INRs during the fi rst 3 months 
of treatment following an acute DVT, which in turn 
predicts a higher rate of subsequent recurrence. 161,175 
The TTR refl ects the quality of dose adjustment in 
studies of patients managed in a usual care (UC) set-
ting, by an anticoagulation management service (AMS), 
by patient self testing (PST) or patient self manage-
ment (PSM), or in the setting of a randomized trial. 
 TTR can be determined in different ways, so com-
parisons between studies may be diffi cult. 176 TTR 
is most commonly estimated by using one of three 
methodologies: calculating the fraction of all INR 
values that are within the therapeutic range (ie, the 
number of INRs in range divided by the total number 
of INR tests); using the “cross-section of the fi les” 
methodology, which assesses the fraction of patients 
with an INR in range at one point in time compared 
with the total number of patients who had an INR 
measured at that point in time; or applying the linear 
interpolation method of Rosendaal et al, 177 which 
assumes that a linear relationship exists between two 
INR values and allocates a specifi c INR value to each 
day between tests for each patient. Each approach 
has its advantages and disadvantages. 176 Furthermore, 
the results of all these methods depend on whether 
without knowledge of genotype. 155-157 Two of these 
studies showed no difference in TTR, whereas one 
study reported increased times in range for the phar-
macogenetic group but had signifi cant design fl aws. 
More recently, Klein et al 158 developed two dosing 
algorithms: one based on clinical variables only and 
one based on both clinical variables and genetic infor-
mation. The ability of these two algorithms to predict 
subsequent warfarin doses was then compared in a 
validation cohort of  . 1,000 patients. The pharmaco-
genetic algorithm more accurately identifi ed patients 
who required   21 mg weekly warfarin doses and 
patients who required weekly doses of   49 mg in 
comparison with the clinical algorithm and to a fi xed-
dose approach, whereas no difference was detected 
in the prediction of intermediate doses. 
 A few studies have suggested that certain geno-
types are associated with adverse events. Thus, 
Higashi et al 29 studied 185 patients, 58 with at least 
one variant genotype of CYP2C9, and found an 
increased risk of having INRs above range (hazard 
ratio [HR], 1.40; 95% CI, 1.03-1.90) and of a serious or 
life-threatening bleeding event (HR, 2.39; 95% CI, 
1.18-4.86) in those with variant genotypes. The latter 
hazard estimate was based on a few events in a very 
small number of patients with the variant genotypes. 
Joffe et al, 159 also studying CYP2C9 single nucleotide 
polymorphisms, found a trend toward increased rates 
of an INR  . 6.0 and of bleeding in patients who were 
categorized as heterozygotes, or compound heterozy-
gotes/homozygotes, compared with those categorized 
as wild type, as did Veenstra et al. 30 A similar increased 
risk of bleeding was seen in patients with these poly-
morphisms who were taking acenocoumarol but 
not phenprocoumon. 32 On the other hand, neither 
CYP2C9 nor VKORC1infl uenced the risk of bleeding 
in a more recent study by Limdi et al. 160 
 Likewise, the only high-quality, randomized, con-
trolled trial performed to date showed that use of a 
pharmacogenetic-based dosing strategy did not sig-
nifi cantly reduce the risk of adverse events (34.7% in 
pharmacogenetic group vs 42.4% in control group; 
OR  5 0.72; 95% CI, 0.41-1.28]). 155 This issue is fur-
ther discussed and recommendations are provided in 
Holbrook et al. 86 
 When rapid anticoagulant effect is required, a rap-
idly acting parenteral anticoagulant should be started 
together with the VKA and discontinued after at least 
5 days of concomitant therapy and once the INR has 
been in the therapeutic range for at least two mea-
surements approximately 24 h apart. This allows fac-
tors X and II to be reduced to levels suffi cient to treat 
VTE. If there is no urgent need for an immediate 
anticoagulant effect (eg, in chronic stable AF), warfa-
rin administration can be commenced without the 
concurrent use of a rapid-acting anticoagulant. 
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both arms of the study. More recently, Witt et al 186,187 
found that patients with very stable INR levels defi ned 
by extremely high TTR rates required fewer visits for 
INR control and had signifi cantly fewer hemorrhagic 
and thromboembolic events than patients with a 
less-stable INR; they suggested that many warfarin-
treated patients whose INR values remain within the 
therapeutic range over time could be safely treated 
with INR recall intervals  . 4 weeks. In this study, 
advanced age predicted stable anticoagulation . 
 1.6.4 Factors Associated With INR Stability in 
Long-term Management:  Two recent studies have 
assessed factors associated with very stable INR 
control during treatment with VKAs. 186,187 In the fi rst 
study, 2,504 patients with INR values entirely within 
the INR range for 6 months were compared with 
3,569 patients with at least one INR value outside the 
INR range. 186 In the second study, 533 patients with 
INR values within the therapeutic range for 12 months 
were compared with 2,555 control subjects. 187 Inde-
pendent predictors of stability were age  . 70 years, 
the absence of chronic diseases, and (in one study 
only 187 ) male gender. Congestive heart failure, dia-
b etes, and a target range for INR   3.0 were associated 
with instability. 
 Physical activity also seems to play a role in the sta-
bility of the response to warfarin. A reduction in the 
anticoagulant effect has been found to be correlated 
with a sudden increase in physical activity. An increase 
in warfarin requirements associated with an increase 
in physical activity (represented by a daily exercise 
such as walking) has been described both in patients 
and in healthy subjects. 188,189 
 Changes in dietary vitamin K intake may infl uence 
the stability of the INR in patients on VKAs, and a 
few trials have assessed its impact on therapeutic 
stability. Sorano et al 190 showed that controlling the 
intake of dietary vitamin K can achieve a more stable 
anticoagulant response. Sconce et al, 191 by comparing 
the daily vitamin K intake in 26 unstable patients and 
in 26 stable control patients, showed that unstable 
patients have poorer intake of vitamin K. Kurnik et al 192 
showed that in vitamin K-depleted patients, very small 
amounts of vitamin K-containing vitamins will infl u-
ence the INR to a greater extent compared with those 
with an adequate vitamin K status. Schurgers et al, 193 
studying healthy volunteers on oral anticoagulation, 
found that a daily dose of vitamin K of at least 150  m g 
was needed to alter the INR response. Reese et al, 194 
in a retrospective analysis, assessed the effect of a 
daily dose of 100  m g of vitamin K 1 in nine unstable 
patients. These patients experienced an increase in 
the percentage of INRs in range from 32% to 57% in 
response to the daily vitamin K. In a prospective, 
open-label, crossover study, Ford et al 195 found that 
an exact or an expanded therapeutic range is used, 178 
whether INRs obtained during invasive procedures 
when warfarin therapy might be interrupted are 
included, and whether different oral anticoagulant 
preparations (eg, warfarin, phenprocoumon, aceno-
coumarol, or fl uindione) are included. 179,180 Since 
clinical outcome studies have not compared one 
methodology with another and correlated their results 
with adverse events, no one method can be recom-
mended, and the reader should be aware of these 
differences. 
 1.6.3 Frequency of Monitoring:  In hospitalized 
patients, INR monitoring is usually performed daily 
until the therapeutic range has been achieved and 
maintained for at least 2 consecutive days. In outpa-
tients starting VKA therapy, initial monitoring may 
be reduced to once every few days until a stable dose 
response has been achieved. When the INR response 
is stable, the frequency of testing can be reduced to 
intervals as long as every 4 to 6 weeks (or possibly 
longer in particularly stable patients). If adjustments 
to the dose are required, then the cycle of more fre-
quent monitoring should be repeated until a stable 
dose response can again be achieved. 
 The optimal frequency of long-term INR moni-
toring is infl uenced by patient compliance, transient 
fl uctuations in the severity of comorbid conditions, 
the addition or discontinuation of other medica-
tions, changes in diet, the quality of dose-adjustment 
decisions, and whether the patient has demonstrated 
a stable dose response. The dose required to main-
tain a therapeutic range for patients  . 60 years of age 
decreases with increasing age, 112,115,181,182 possibly 
because of a reduction in the clearance of warfarin 
with age. 183 Gender also infl uences dose, with women 
requiring less warfarin to maintain a therapeutic INR 
than men at an equivalent age. 115 
 To compare different intervals between measure-
ments of INR in stable patients, Pengo et al 184 ran-
domized 124 patients with prosthetic mechanical 
heart valves and at least 6 months of a steady dose 
requirement to INR monitoring at either 6-week or 
4-week intervals. They found no differences of 
time in, above, or below range between the groups, 
although the actual monitoring intervals were 
24.9 days in the 6-week group and 22.5 days in the 
4-week group ( P  , .0003). 184 In a retrospective study 
of  . 4,000 patients with chronic AF and  . 250,000 INRs, 
Shalev et al 185 found that time in range increased as 
the testing interval decreased from every 5 weeks or 
more to every 3 weeks (41% to 48%,  P  , .0005), and 
the investigators suggested that patients should be 
monitored at time intervals no longer than every 
3 weeks. However, the strength of the recommenda-
tion is reduced by the very poor TTR reported in 
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In a case-control study on the most unstable patients 
from 35 Italian ACs, poor comprehension of the 
indications and mechanisms of VKAs was the most 
important predictor of instability among other fac-
tors, including working status, type of VKA, and a 
poor score on a mental test. 161 In a single-center study 
carried out on outpatients attending an AC in the 
United States, perceived barriers to compliance with 
warfarin, marital status, living arrangements, and 
drug regimen played signifi cant roles in warfarin 
noncompliance. 201 In a prospective cohort study of 
adults initiating warfarin at two ACs, independent 
risk factors for nonadherence were education level, 
employment status, mental health functioning, and 
cognitive impairment. 202 
 1.7 Data Management 
 An obstacle to the safety and effectiveness of war-
farin therapy is the poor quality of dose management 
in routine clinical practice. Adequate anticoagulant 
care with the VKAs requires a system of patient edu-
cation and careful data management to record and 
track INR values and to ensure patients are treated 
with anticoagulants for an appropriate period of time. 
 1.7.1 The Role of Anticoagulation Clinics:  Nonran-
domized, retrospective studies have reported better 
outcomes in patients when anticoagulant therapy is 
managed by an AMS or an AC compared with man-
agement by their personal physicians (ie, UC). Four 
such studies have reported major bleeding rates 
rang ing from 2.8% to 8.1% per patient-year of 
UC. 203-206 Rates of thromboembolism with UC were 
not reported except in two studies in which the event 
rates were 6.2% and 8.1% per patient-year. Similarly, 
retrospective and prospective cohort studies of care 
provided by an AMS reported rates of major hem-
orrhage or thrombosis ranging from 1.4% to 3.3% 
and 0.7% to 6.3% per patient-year of therapy, respec-
tively. 164,170,207-210 Three retrospective comparative stud-
ies using a before-and-after design of patients managed 
by UC or an AMS reported signifi cant improvements 
in the outcomes of hemorrhage or thrombosis with 
AMS-directed care. 211-213 In contrast, however, two 
prospective, randomized controlled trials 214,215 com-
paring UC with the care of an AMS failed to show 
a signifi cant difference in major hemorrhage or 
thromboembolism. The study by Matchar et al 214 also 
failed to show a signifi cant improvement in TTR, 
although the AMS performed modestly better than 
UC. Wilson et al 215 did observe a signifi cant improve-
ment in TTR in the AMS group compared with UC 
(82% vs 76% respectively,  P  5 .034). They also noted 
more high-risk INRs with UC than with an AMS 
(40% vs 30%,  P  5 .005). This latter study had a major 
fi ve of nine patients improved their stability with 
administration of low-dose vitamin K. As expected, 
the INR initially decreased in patients given vitamin K, 
and an increased dose of warfarin was needed to 
reestablish an INR within the therapeutic range, which 
took from 2 to 35 days to achieve. In a nested case-
control study, Rombouts et al 196 assessed the effect of 
dietary vitamin K intake on the risk of subtherapeutic 
INR values and the interaction between usual and 
recent vitamin K intake. Patients with a high usual 
vitamin K intake had less risk of a subtherapeutic 
INR, an effect possibly mediated by a reduced infl u-
ence on the INR of an incidental consumption of 
vitamin K-rich food when there is a high usual intake 
of vitamin K. In these last two studies, variable INR 
was defi ned as requiring a minimum of three warfa-
rin dose changes or three INRs outside of the thera-
peutic range in the preceding 6 months, 195 or an INR 
SD  . 0.5 with at least three warfarin dose changes 
during the previous 6 months. 196 
 Sconce et al 197 conducted the fi rst randomized, 
blinded trial in 70 unstable patients over a 6-month 
period. Vitamin K supplementation with 150  m g/d 
resulted in a signifi cantly greater decrease in SD 
of the INR compared with placebo ( 2 0.24   0.14 
vs  2 0.11   0.18;  P  , .001) and a signifi cantly greater 
increase in percentage of time within target INR 
range (28%   20% vs 15%   20%;  P  , .01). Finally, 
Rombouts et al 198 randomized 100 patients treated 
with phenprocoumon to receive daily doses of 100  m g 
of vitamin K and 100 patients to receive a placebo. 
Vitamin K improved the stability of anticoagulant 
therapy, with a relative risk of maximal stability 
(where all INR results were in range) in the vitamin K 
group compared with the placebo group of 1.8 
(95% CI, 1.1-2.7). 
 De Assis et al 199 randomized patients with a recent 
INR value outside the therapeutic range to a conven-
tional approach based on changes in anticoagulant 
prescription or to a strategy that adjusted the dietary 
intake of vitamin K. Patients in the latter group had 
signifi cantly more INR values within the therapeutic 
range and signifi cantly fewer episodes of minor 
bleeding as compared with patients in the former 
group. 
 As with any other drug, a patient’s nonadherence 
to prescribed dosing with VKAs is one of the most 
important causes of INR instability. In a prospective 
cohort study at three US ACs aimed to determine 
the effect of adherence on anticoagulation control, 
patients treated with warfarin were monitored with 
an electronic system that records each time they open 
their medication container. 200 There was a high pro-
portion of missed tablets and, as expected, in multi-
variable analyses there was a signifi cant association 
between under-adherence and under-anticoagulation. 
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proved comparable to manual regulation in terms 
of the percentage of INR values maintained within 
the therapeutic range but required 50% fewer changes 
of dose. The fi rst multicenter randomized trial, in 
285 patients, of one computerized dosage program 
in 1998 223 showed a 22% overall improvement of con-
trol with the program compared with the perfor-
mance of experienced medical staff. The computer 
program gave signifi cantly better overall INR control 
across all target INR ranges. A slight improvement 
in TTR was also obtained by Italian investigators 224 
using a different management program in  . 1,200 ran-
domized patients from fi ve centers. A total of 71.2% 
of patients were in range with computer dosing and 
68.2% were in range by manual dosing during the 
maintenance phase. 224 In both of these studies, the 
computer’s improved results were probably due, in 
part, to a reduced propensity to reduce warfarin 
doses when the INR was at the upper limit of the 
“desired” range. 
 More recently, the European Concerted Action 
on Anticoagulation completed the fi rst international, 
multicenter, randomized, controlled trial aimed to 
compare the safety and effectiveness of computer-
assisted dosing of VKAs, using two computer pro-
grams in different centers (DAWN AC; 4S Information 
Sys, and PARMA; Instrumentation Laboratories), 
with conventional manual dosing. 225 A total of 
13,052 patients treated with a VKA were followed for 
a total of 18,617 patient-years. Overall, there was a 
trend toward fewer clinical events with computer-
assisted dosage. There was also a statistically signif-
icant reduction in clinical events in the subgroup 
treated for VTE. A subsequent cost-effectiveness 
analysis found computer-assisted dosing cheaper than 
manual dosing. 226 
 The results of two small clinical trials suggest 
that computerized dose management can also be at 
least as effective as manual dosing by trained antico-
agulation physicians or nurses during the initiation 
of anticoagulation therapy. 224,227 However, some com-
puterized programs are unable to manage dosing 
during the induction phase. 
 1.7.3 Point of Care INR Testing:  Point of care 
(POC) monitors measure a thromboplastin-mediated 
clotting time using a fi ngerstick sample of capillary 
whole blood or un-anticoagulated venous whole 
blood. 228 The result is then converted to a plasma 
PT equivalent by a microprocessor and is expressed 
as a PT and/or INR. Each manufacturer typically 
establishes the conversion formula by simulta-
neously comparing fi ngerstick or venous whole blood 
results with an established laboratory method and 
reagent that is traceable to the international refer-
ence thromboplastin. 
limitation in that all patients were initially managed 
in an AMS for 3 months until they were stable and 
then observed for only 3 months after randomiza-
tion to either receive UC or to continue care by 
the AMS. 215 The other study 214 suffered from a high 
turnover of patients, the possibility of selection bias 
affecting the referral of patients to the AMS, the open 
nature of the study, and targeted ranges that were 
sometimes outside recommended guidelines. In a 
retrospective, multicenter, international cohort study, 
1,511 patients were randomly recruited from clinics 
offering routine medical care (UC) in the United 
States, Canada, and France, and from ACs in Italy 
and Spain. 216 Major management differences were 
detected, especially between AC care and routine 
medical care, but also among countries. For patients 
managed by routine medical care, documentation of 
care was often inadequate. Finally, less time in thera-
peutic INR range was noted in routine medical care. 
 In a systematic review of 67 studies represent-
ing  . 50,000 patients managed by ACs (68%), during 
clinical trials (7%), or in community practices (24%), 
van Walraven et al 217 found that the practice setting 
had the greatest effect on anticoagulation control. 
TTR (days) varied from 56.7% in community prac-
tices to 65.6% in ACs and 66.4% for randomized 
trials. Compared with randomized trials the abso-
lute reduction of TTR for community practices was 
 2 12.2% (95% CI,  2 19.5 to  2 4.8). The difference 
between community practices and ACs was  2 8.3% 
(95% CI,  2 4.4 to  2 12.1). 
 1.7.2. Computerized Monitoring:  Computer assis-
tance by the use of dedicated programs may improve 
dose management and TTR. Although programs 
differ, they typically calculate whether a dose adjust-
ment is necessary from a user-defi ned table of trend 
rules for each therapeutic range. If dose adjustment 
is required, the current INR is compared with the 
target INR, and a proprietary equation calculates the 
new dose. The time to the next test is also set by the 
program using a set of variables comparing the cur-
rent INR, the interval from the last test, the number 
of previous changes, and the number of previous INR 
values within the target range. 
 A number of early studies 218-220 evaluated computer 
programs to improve warfarin dosing. The fi rst ran-
domized study in 1993 221 showed that three contem-
porary computer programs all performed as well as 
the experienced medical staff of an anticoagula-
tion management service in achieving a target INR 
of 2.0 to 3.0, but the computer achieved signifi cantly 
better control when more intensive therapy was 
required (ie, INR, 3.0-4.5). In another randomized 
study 222 of 101 patients receiving long-term antico-
agulation, computerized warfarin dose adjustment 
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European Concerted Action on Anticoagulation has 
recently tested 523 Coaguchek monitors at nine clinics 
and found that 20.3% of the monitors showed signifi -
cant deviations. 257 
 PST or PSM using a POC instrument represents 
another model of care with the potential for improved 
outcomes as well as greater convenience. 258 Several 
systematic reviews have shown improvements in the 
quality of anticoagulation control (TTR) and/or inci-
dence of adverse events with PST and/or PSM. 259-261 
Heneghan et al 261 pooled estimates from 14 random-
ized trials of PST showing a signifi cant reduction in 
thromboembolic events (OR, 0.45; 95% CI, 0.30-0.68), 
all-cause mortality (OR, 0.61; 95% CI, 0.38-0.98), 
and major hemorrhage (OR, 0.65; 95% CI, 0.42-0.99) 
vs the comparator. For PST and PSM combined, 
there were signifi cant reductions in thromboembolic 
events (OR, 0.27; 95% CI, 0.12-0.59) and death (OR, 
0.37; 95% CI, 0.16-0.85) but not major hemorrhage 
(OR, 0.93; 95% CI, 0.42-2.05). In a recent ran-
domized study from France comparing monthly 
laboratory monitoring with weekly self testing and 
monitoring in patients with prosthetic heart valves, 
self monitoring improved INR stability and reduced 
the incidence of bleeding, although the study was 
underpowered to show a true difference in clinical 
outcomes. 262 Another recent randomized study from 
Germany compared INR monitoring by the primary 
care physician with self management in patients with 
prosthetic heart valves and found greater INR stability 
and a lower incidence of thromboembolic events in 
the group of self-managed patients but no differences 
in bleeding events. 263 
 PST and PSM require special patient training 
to implement. 264,265 This mode of therapy may not be 
suitable for all patients and may not be practical or 
cost-effective in certain settings. All participants in 
PST/PSM programs should participate in a recog-
nized external quality assessment program. 
 1.8 Optimal Intensity Ranges 
 The optimal target range for the INR is not the 
same for all indications. In general, because bleed-
ing is closely related to the intensity of anticoagula-
tion, 164,266-268 there has been interest in establishing 
the lowest effective therapeutic range for each 
indication. 268-276 
 Investigators have used various methodological 
approaches to establish the most appropriate range 
for different indications. These are as follows: (1) ran-
domized trials in which patients are assigned to one 
of two different target ranges 270-274 ; (2) indirect com-
parisons, in which outcomes are compared between 
separate randomized trials of VKA therapy that 
applied different target ranges of INR, and the control 
 Numerous studies 229-248 have reported on the accu-
racy and precision of these instruments and on the 
ability of patients, both adults and children, to obtain 
an INR and to use that INR to guide their anticoagu-
lant therapy. However, limitations to the accuracy and 
precision of POC INR monitors have been documented. 
Problems identifi ed with POC instruments include 
greater differences compared with a standard plasma-
based methodology as INRs increase above the 
therapeutic range, 242,243 incorrect calibration of the 
ISI of the POC instruments, 244 the inability to cal-
culate a mean normal PT, 249 and instrument-specifi c 
inaccuracies of the INR in patients with antiphospho-
lipid antibodies. 250 In a recent systematic review of 
the literature, Gialamas et al 251 concluded that there 
is still no robust evidence that the use of POC instru-
ments in general practice improves health outcomes 
or is cost-effective compared with UC and that ana-
lytical quality is comparable to laboratory testing. A 
major problem of comparative studies is the fact that 
there is a similar lack of correlation of INR results 
when anticoagulated plasmas are simultaneously com-
pared using different instrument/thromboplastin 
combinations. 129-135 These differences may be clini-
cally important in that they may lead to different 
dosing decisions. 128-134 Kaatz et al 252 compared two 
POC monitors and four clinical laboratories against 
a secondary reference thromboplastin preparation. 
They found that laboratories using a more sensitive 
thromboplastin showed close agreement with the 
standard, whereas laboratories using an insensitive 
thromboplastin showed poor agreement. The two 
POC monitors fell between these two extremes. 
 Steps are still needed to ensure the conformity of 
POC PT monitors to the WHO INR PT standardi-
zation scheme, but the WHO ISI calibration proce-
dure is not practicable using the monitors. Simpler 
procedures for ISI calibration of POC monitors have 
recently been evaluated in a number of multicenter 
sites by the European Concerted Action on Anti-
coagulation and the UK National External Quality 
Assessment Schemes. By using lyophilized plasma 
calibrants with independently certifi ed INRs, Poller 
and colleagues 253-255 have shown that verifi cation or 
recalibration of the ISI of the instrument is possible. 
However, to obtain reliable ISI values for the two 
instruments tested they had to develop different 
ISI calibration methods. It is likely, therefore, that 
different types of POC monitor systems will require 
different ISI calibration methods. In a study of profi -
ciency testing of three POC monitors over 6 years 
in  . 10 centers, Kitchen et al 256 found in each survey 
that INR results in 10% to 11% of centers were  . 15% 
different from results in other centers using the same 
monitors. This compared with a 12% difference for 
hospitals using conventional INR techniques. The 
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INR testing, changes in vitamin K intake, changes in 
the absorption of vitamin K or VKAs, changes in the 
metabolism of VKAs, changes in vitamin K-dependent 
coagulation factor synthesis or metabolism, other 
effects of concomitant drug use, or patient noncom-
pliance. A number of studies have shown that adverse 
event rates rise sharply as the INR moves above or 
below the target INR interval. 163,164,174 A recent retro-
spective analysis of  . 3,000 patients with AF found 
that the one-third with the poorest INR control 
(48% of time in range) had twice the rate of stroke, 
myocardial infarction, major bleeding, and death as 
did the one-third with the best INR control (83% of 
time in range). 163 
 However, the risk of adverse events associated with 
a single INR outside the therapeutic range is probably 
low. For example, although excessively elevated INR 
values are clearly associated with an increased risk of 
bleeding, in particular for INR values of  . 5.0, 164,169,170,268 
data from a large registry of warfarin-treated patients 
suggest that the short-term risk for major bleeding 
is low for someone with a single INR value between 
5.0 and 9.0 (0.96% at 1 month). 291 Similarly, in a ret-
rospective, matched cohort study of 2,597 patients on 
warfarin therapy, the risk of thromboembolic events 
at 3 months in patients with stable INRs who experi-
enced a single signifi cant subtherapeutic INR value 
was low (0.4%) and was not signifi cantly different 
from the risk observed in patients with persistently 
stable INRs. 292 Similar rates were reported in a popu-
lation of 294 patients with mechanical heart valves 
experiencing a single subtherapeutic INR and in a 
large cohort of patients who required short-term dis-
continuation of warfarin to undergo minor outpatient 
interventions. 293,294 
 Before executing a plan for managing an episode 
of altered anticoagulation effect, important factors 
relating to the collection and processing of the blood 
sample must be taken into consideration. For exam-
ple, a spuriously elevated INR should be suspected 
when a patient with previously stable INR control 
presents with a very high INR result in the absence of 
any explanation for the loss of INR control. Spurious 
results might also be suspected when abnormalities 
were encountered during sample collection (eg, the 
phlebotomist had a diffi cult time obtaining a sample 
or combined the contents of two collection tubes, 
and so forth). 295 Recommendations for the manage-
ment of patients whose INR is outside the therapeutic 
range are provided in Holbrook et al. 86  
 1.10 Adverse Events 
 1.10.1 Bleeding Events:  The rate of hemorrhagic 
events must be interpreted in the context of the clin-
ical characteristics of the group studied. Factors that 
patients received no therapy or another antithrom-
botic agent (usually aspirin) 277-280 ; (3) subgroup analyses 
of observational studies (including within treatment 
groups of randomized trials) relating the observed 
INR or time spent in an INR range at the time of the 
outcome to either a bleeding event or thromboem-
bolic event 164,207,208,267,268,281 ; and (4) case-control studies 
in which the INR levels at the time of an event are 
recorded and compared with INR levels in appropri-
ately selected control subjects. 174 
 When moderate-intensity INR (approximately 
2.0-3.0) was compared with higher-intensity adjusted-
dose oral anticoagulation, 269,272-274,278-280 the moderate 
treatment intensity was shown to reduce the risk of 
clinically important bleeding without reducing effi -
cacy. Conversely, a lower treatment intensity (eg, 
INR range 1.5-2.0) appears to be less effective than 
moderate-intensity therapy. For example, a random-
ized trial demonstrated that an INR of  , 2.0 (INR 
target, 1.5-2.0) 270 reduced the recurrence of venous 
thrombosis after an initial 3 to 6 months of standard 
treatment when compared with placebo. A subse-
quent clinical trial, 271 however, found that maintain-
ing an INR intensity of 2.0 to 3.0 in the same clinical 
setting was more effective than a lower intensity 
of 1.5 to 2.0 and was not associated with a greater risk 
of bleeding. Likewise, in patients with AF, a ran-
domized trial 282 reported that adjusted-dose warfarin 
therapy (INR, 2.0-3.0) was more effective than the 
combination of fi xed-dose warfarin (3 mg/d) and aspi-
rin; other studies showed that the effi cacy of oral 
anticoagulant agents is reduced when the INR falls 
to  , 2.0. 174,207,208,283-285 Warfarin targeted to an INR 
of  , 2.0 has also been shown to be ineffective for pre-
venting failure of dialysis access grafts. 286 
 The use of fi xed minidose warfarin (1 mg daily) has 
been evaluated in a number of clinical settings. A num-
ber of these studies reported that fi xed minidose war-
farin is ineffective when compared with dose-adjusted 
warfarin, in particular for the prevention of stroke in 
patients with AF and for the prevention of thrombo-
sis of central venous catheters. 287-290 There is currently 
no evidence to support the use of fi xed mini-doses of 
either acenocoumarol or phenprocoumon in any set-
ting. However, the data obtained with fi xed minidoses 
of warfarin cannot be extrapolated to other VKAs 
because of their different half-lives and the likelihood 
they would have different pharmacodynamic effects 
at similar doses. The optimal target range for each 
indication is discussed specifi cally in other articles in 
this supplement pertaining to each indication. 
 1.9 Signifi cance of Nontherapeutic INRs 
 Fluctuations in INR may occur because of any one 
or more of the following conditions: inaccuracy in 
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Of these patients, 27 receiving anticoagulant therapy 
(84%) and eight control patients (73%) were found to 
have signifi cant underlying disease, with three can-
cers found in the combined group (7%). Other case 
series 301,302 have reported a higher likelihood of under-
lying lesions in patients who develop hematuria while 
receiving anticoagulant therapy. 
 1.10.2 Factors Predictive of Bleeding Events:  The 
most important factor infl uencing the risk of bleeding 
is the intensity of anticoagulant therapy. 162,164,169,170,174,
208,266-269,272-275,283-285 The likelihood of bleeding has been 
reported to rise steeply as the INR increases above 
5.0. 164,169,170,268 The optimal target range for each indi-
cation and the lowest effective range are discussed 
specifi cally in other articles in this supplement per-
taining to each indication. 
 Several patient characteristics are associated with 
higher odds of bleeding during anticoagulation ther-
apy. The patient factor most consistently predictive 
of major bleeding is a history of bleeding (especially 
GI bleeding). 162,208,273 Other factors associated with 
a higher risk of bleeding include advanced age; the 
presence of a serious comorbid condition, such as 
cancer, renal insuffi ciency, liver disease, arterial hyper-
tension, and prior stroke; alcohol abuse; and the use 
of concomitant therapies, in particular antiplatelet 
drugs. 162,203,204,207,303 
 A number of prediction models of bleeding risk 
have been proposed. Dahri and Loewen 304 performed 
a qualitative review of the published clinical predic-
tion rules that estimated bleeding risk in patients 
starting on warfarin. The authors found seven studies, 
of which four presented distinct clinical prediction 
rules. Because none of these scores exhibited suffi -
cient predictive accuracy or evaluated the impact of 
their use on patient outcomes, the authors concluded 
that no existing clinical prediction rules can be rec-
ommended for widespread use in practice at present. 
One prediction model that was prospectively vali-
dated in different outpatient populations identifi ed 
four independent factors associated with an increased 
risk of bleeding. These factors were age  . 65 years, 
history of gastrointestinal bleeding, history of stroke, 
and at least one of the following variables: myocardial 
infarction, hematocrit  , 30%, creatinine  . 1.5 mg/dL, 
and diabetes. 203 Another model, derived using registry 
data from patients with AF, identifi ed prior bleeding, 
hepatic or renal disease, ethanol abuse, malignancy, 
age  . 75 years, reduced platelet count or function, 
hypertension (uncontrolled), anemia, genetic factors 
(CYP2C9 polymorphism), an excessive risk of falls, 
and a history of stroke as risk factors for bleeding. 305 
 The impact of age on bleeding risk remains contro-
versial, with older reports fi nding risk increasing with 
age, 162,163,181,267,306,307 whereas newer studies have failed 
infl uence the rate of bleeding include the following: 
the target INR range; whether patients are mostly 
new to therapy or have long-term experience with 
therapy; whether an INR or PT is used to manage 
therapy; the indication for anticoagulation; the type 
of VKA; patient-specifi c risk factors, including con-
comitant antiplatelet therapy; and the quality of dose 
management. It is also not appropriate to extrapolate 
the rates of adverse events from randomized con-
trolled trials to everyday practice, because high-risk 
patients may be excluded from clinical trials, and moni-
toring and management of anticoagulation are often 
better coordinated in clinical trials than in clinical 
practice. 
 When bleeding occurs, especially from the GI or 
urinary tract, the presence of an underlying occult 
lesion should always be considered. This is important 
because the patient factor that most consistently pre-
dicts major bleeding is a history of other bleeding, 
particularly from the GI tract. 207 A number of descrip-
tive studies 296-298 have reported on the probability of 
fi nding occult lesions. Coon and Willis 296 identifi ed 
occult lesions that were responsible for bleeding in 
11% of 292 patients with hemorrhage. Jaffi n et al 297 
found a 12% prevalence of positive stool occult blood 
test results in 175 patients receiving warfarin or hep-
arin compared with 3% in 74 control subjects. There 
was no difference between the mean PT or activated 
partial thromboplastin time (aPTT) in patients with 
positive and negative test results. Among the patients 
with positive stool occult blood test results, 15 of 
16 patients had a lesion that had not been previously 
suspected, and four patients had neoplastic disease. 
Landefeld et al 266 found that 14 of 41 patients with GI 
bleeding had important remediable lesions, of which 
two were malignant. To perform endoscopy in these 
patients is an important choice, because endoscopy 
has been shown in prospective studies to identify the 
bleeding source in  . 50% of patients managed with 
anticoagulant therapy who present with upper GI 
tract bleeding and because endoscopic therapy for 
nonvariceal upper GI bleeding achieves hemostasis 
in  . 90% of patients. 299 This limited information sup-
ports the need to investigate patients with occult GI 
bleeding, as it may herald the presence of an under-
lying malignancy or other lesion that is frequently 
rectifi able. 
 In a 2-year prospective study in which enrolled 
patients had monthly urinalysis, Culclasure et al 300 
found microscopic hematuria in 3.2% of patients 
receiving oral anticoagulation compared with 4.8% in 
the control group not receiving anticoagulant therapy. 
There was no difference in the rate of hematuria with 
therapeutic or high INRs. Following a second epi-
sode of hematuria, 43 patients (32 receiving anticoag-
ulant therapy, 11 control patients) were investigated. 
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one) and blood derivatives such as fresh frozen plasma 
and prothrombin complex concentrates and recom-
binant activated factor VII. 303,320 
 Interruption of VKAs may be suffi cient in patients 
who need an elective invasive procedure or in asymp-
tomatic patients with an elevated INR value and a 
low risk for bleeding. In this latter case, it must be 
noted that it takes approximately 2.5 days for an INR 
between 6.0 and 10.0 to decline to  , 4.0. 321 Because 
acenocoumarol has a much shorter half-life than war-
farin, the time required for an effective decline will 
be less and is probably no more than 1 day for most 
patients. 322,323 Conversely, the longer half-life of phen-
procoumon will probably result in a much slower 
decline. Finally, the half-life of fl uindione is similar to 
that of warfarin, and thus a similar decline should be 
expected. 
 Phytonadione (vitamin K 1 , a form of vitamin K 
derived from plants) has been used in clinical trials 
that assessed the usefulness of oral vitamin K for 
the treatment of warfarin-associated coagulopathy. 324 
Vitamin K 2 (menaquinone, which is synthesized by 
bacteria) and vitamin K 3 (menadione) are not widely 
available and have not been well studied in clinical 
trials. 324 Low doses of phytonadione can be adminis-
tered orally in combination with warfarin interrup-
tion in patients not requiring urgent reversal. When 
oral phytonadione is administered in conjunction with 
temporary interruption of warfarin therapy, approxi-
mately 1.4 days are required for an INR between 
6 and 10 to decline to  , 4.0. 321 When administered 
intravenously, low doses of phytonadione produce sim-
ilar reductions as oral phytonadione in the INR value 
at 24 h, whereas subcutaneous phytonadione appears 
to be less effective than low-dose oral 
phytonadione. 325,326 When administered at higher 
doses for the management of the bleeding patient, 
intravenously administered phytonadione works 
more rapidly than either oral or subcutaneous vitamin 
K 1 . 325,327,328 Reduction of the INR begins within 2 h, 
and a correction to within the normal range is gener-
ally achieved within 24 h if hepatic function is normal 
and if a suffi ciently large dose is given. 324 At 24 h, 5 
mg of oral and 1 mg or IV vitamin K 1 produce sim-
ilar effects on the INR. 325 IV phytonadione may 
cause anaphylactoid reactions. Although frequently 
reported, and likely more common in patients who 
receive large IV doses administered rapidly, the 
true frequency of this complication is about three 
per 10,000 doses administered, and it may be more 
likely to occur if formulations containing polyethoxy-
lated castor oil are used to maintain the vitamin K in 
solution. 329 To minimize the risk of anaphylactoid 
reactions, vitamin K 1 should be mixed in a minimum 
of 50 mL of intravenous fl uid and administered, using 
an infusion pump, over a minimum of 20 min. 
to fi nd this association. 170,205,207,268,282,308-310 The discrep-
ancy may be partly explained by the wide range in the 
mean age of the patients enrolled in the various studies, 
the relative lack of representation in most studies of 
patients  . 80 years of age, and the selection and survi-
vorship biases in noninception cohort studies. When 
investigators attempt to separate the effect of age from 
comorbid conditions associated with age, some have 
concluded that age in and of itself is not a major inde-
pendent risk factor, 112,267,311 whereas others have found 
it to be an independent risk factor 266,268 even after con-
trolling for the intensity of the anticoagulant effect. 
Some have suggested that older patients may have a 
lower risk of bleeding when managed by AMS. 312,313 
Even if the overall risk of bleeding is not increased in 
the elderly, it is clear that the risk of intracranial hem-
orrhage increases with age. 267,268,314,315 
 Warfarin is frequently used concurrently with other 
antithrombotic agents. A meta-analysis assessing clin-
ical studies comparing warfarin alone and warfarin in 
association with aspirin found that the combination 
increased the risk of bleeding by almost one-half 
compared with warfarin alone (OR, 1.43; 95% CI, 
1.00-2.02 ). 316 A combined analysis of the SPORTIF 
(Stroke Prevention Using an Oral Thrombin Inhib-
itor in Atrial Fibrillation) III and V trials involving 
481 patients who received aspirin and warfarin com-
pared with 3,172 patients who received warfarin alone 
demonstrated a signifi cant 1.6% per year increase in 
major bleeding. 317 Although there are no randomized 
controlled trials that have compared bleeding rates 
in patients receiving “triple therapy” (usually warfa-
rin, aspirin, and clopidogrel) with either warfarin 
alone or with a “dual therapy,” a systematic review 
identifi ed 12 reports involving 3,413 patients treated 
with oral anticoagulants who underwent percutaneous 
coronary intervention with stent insertion and subse-
quently received the combination of aspirin, clo-
pidogrel, and warfarin. The rates of major bleeding 
in patients receiving triple therapy ranged from 
0% to 21% (mean 7.4%) during up to 21 months of 
follow-up and 0% to 5.9% (mean 2.6%) during 30 days 
of follow-up. 318 In a Danish nationwide registry of 
patients with AF, all combinations of warfarin, aspi-
rin, and clopidogrel were associated with an increased 
risk of nonfatal and fatal bleeding, whereas dual or 
triple therapy carried a more than threefold higher 
bleeding risk than warfarin alone. 319 
 1.10.3 Reversal Strategies:  Strategies to reverse the 
effect of VKAs may be needed in patients who require 
urgent invasive procedures, in asymptomatic patients 
presenting with excessively elevated INR values, and 
in bleeding patients. Therapeutic options include 
interruption of VKA treatment as well as the admin-
istration of vitamin K (usually vitamin K1, phytonadi-
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the subcutaneous fat (in the case of skin necrosis) and 
massive outfl ow obstruction of the venous circulation 
of the limb (in the case of limb gangrene). The path-
ogenesis of these complications and the reason for 
the localization of the lesions are not well understood. 
An association between warfarin-induced skin necro-
sis and protein C defi ciency 336-339 and, less commonly, 
protein S defi ciency 339 has been reported, but this 
complication also occurs in nondefi cient individuals. 
A pathogenic role for protein C defi ciency is sup-
ported by the similarity of the lesions to those seen 
in neonatal purpura fulminans, which complicates 
homozygous protein C defi ciency. A variant of this 
syndrome also attributed to a severe warfarin-induced 
depletion of protein C is the occurrence of venous 
limb gangrene during warfarin treatment of cancer-
associated DVT 340 and in some patients with heparin-
induced thrombocytopenia started on warfarin after 
withdrawal of heparin. 341,342 The management of patients 
with warfarin-induced skin necrosis who require life-
long anticoagulant therapy is problematic. Therapy 
with warfarin is considered to be contraindicated, 
and long-term heparin therapy is inconvenient and is 
associated with osteoporosis. A reasonable approach 
in such patients is to restart warfarin therapy at a low 
dose (eg, 2 mg), under the coverage of therapeutic 
doses of parenteral anticoagulants, and to gradually 
increase the warfarin dose over 1 or more weeks. This 
approach should avoid an abrupt fall in protein C 
levels before there is a reduction in the levels of fac-
tors II, IX, and X, and it has been reported to not be 
associated with the recurrence of skin necrosis in a 
number of case reports. 337,338,342 
 The purple toe syndrome may very rarely occur in 
association with the initiation of VKA treatment. It 
is a nonhemorrhagic, cutaneous complication due to 
cholesterol emboli that usually develops 3 to 8 weeks 
after the start of warfarin therapy and is character-
ized by the sudden appearance of bilateral, painful, 
purple lesions on the toes and sides of the feet that 
blanch with pressure. 343,344 
 The VKAs also interfere with the carboxylation 
of Gla proteins that are synthesized in bone. 345-348 
Although these effects contribute to fetal bone abnor-
malities when mothers are treated with a VKA dur-
ing pregnancy, 349,350 it is unclear how they might affect 
children. There are two uncontrolled cohort stud-
ies that describe reduced bone density in children 
on warfarin for  . 1 year, but the role of the under-
lying disorders in reducing bone density remains 
unclear. 351 
 Finally, by preventing the activation of G1a proteins 
and growth arrest-specifi c gene 6 (Gas-6), VKAs may 
also induce vascular calcifi cation. 352 However, this 
relationship in humans is conjectural and is based on 
case reports. 352 
 Fresh frozen plasma remains the most widely used 
coagulation factor replacement product for urgent 
reversal of coumarin anticoagulation. 320 Plasma may 
be a potential carrier of infective agents, and its use is 
associated with an increased risk of volume overload. 
Furthermore, it requires a cross-match if group-specifi c 
plasma is to be used, and it takes a prolonged period 
of time to thaw and administer. Given the long half-
life anticoagulant effect of warfarin and the short 
half-life of infused coagulation factor concentrates, 
phytonadione must also be given to restore the ade-
quate endogenous production of VKA-sensitive 
anticoagulant proteins. Urticaria occurs frequently 
with plasma transfusion; anaphylaxis is less common, 
occurring in about one in 20,000 transfusion epi-
sodes. 330 Transfusion-related acute lung injury remains 
the most feared complication after transfusion and is 
estimated to occur in about one in 5,000 plasma-
containing transfusions. 331 
 Nonactivated prothrombin complex concentrates 
(PCC) are probably more effective than plasma in cor-
recting INR. PCCs do not require a cross-match, are 
virally inactivated, do not pose a risk of volume over-
load, and can be infused in 15 to 30 min. PCC may be 
classifi ed as three-factor products (with adequate 
levels of factors II, IX, X, and low factor VII levels) 
and four-factor products, which contain adequate 
levels of factors II, VII, IX, and X as well as protein C 
and S. 319,331 Current PCCs are more or less devoid 
of activated clotting factors and are supplemented 
with heparin and antithrombin to minimize the risk 
of thrombosis. 332 Four-factor PCCs are currently not 
available in some countries (eg, United States). 
 In patients with life-threatening bleeding, recom-
binant activated factor VII has been used to control 
bleeding. 320 Recombinant activated factor VII is able 
to generate a consistent thrombin burst through both 
tissue factor-dependent and tissue factor-independent 
mechanisms and is able to trigger thrombin generation 
even in the presence of signifi cant platelet dysfunc-
tion. Evidence supporting its use in VKA-associated 
bleeding is currently limited, and its use cannot be 
recommended except in the setting of life-threatening 
bleeding when more effective agents are not avail-
able. 333 As would be expected based on its potent pro-
coagulant effect, this agent may cause thrombosis. 
Recommendations to guide the use of these strat-
egies are provided in Holbrook et al. 86  
 1.10.4 Nonhemorrhagic Adverse Events:  Other 
than hemorrhage, the most important side effects of 
warfarin are acute thrombotic complications, such as 
skin necrosis and limb gangrene. These uncommon 
complications are usually observed on the third to 
eighth day of therapy 334,335 and are caused by exten-
sive thrombosis of the venules and capillaries within 
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tion site (exosite 1). 356 Because the highly polar and 
lipophobic dabigatran molecule is not absorbed from 
the gut, its oral availability required the synthesis of 
an absorbable prodrug, dabigatran etexilate (BIBR 
1048; 627.7 d). 357 On absorption, this esterifi ed, hexy-
lated, and more lipophilic prodrug is rapidly con-
verted to dabigatran (the mechanism is ester cleavage 
catalyzed by serine esterase enzymes, via two inter-
mediates—BIBR 1087E and BIBR 951 CL). 357,359 As 
would be expected from a direct thrombin inhibitor, 
dabigatran prolongs the thrombin clotting time 
(TCT), PT, aPTT, and ecarin clotting time (ECT) of 
plasma from humans, rats, rabbits, dogs, and rhesus 
monkeys and also inhibits thrombin generation in 
human plasma. 358 The ECT has been a preferred 
measure of anticoagulant effect for r-hirudin and other 
direct thrombin inhibitors; ecarin is a metallopro-
tease enzyme obtained from venom of the saw-scaled 
viper ( Echis carinatus ) that generates meizothrom-
bin from prothrombin. 360,361 
 Dabigatran prevents thrombin-induced platelet 
aggregation but not platelet aggregation by arachi-
donic acid, collagen, or adenosine diphosphate. 358 
Administration of oral dabigatran etexilate or IV dab-
igatran causes concentration-dependent reductions 
of thrombosis provoked in rats and rabbits by venous 
stasis plus tissue factor infusion or venous stasis 
plus endothelial damage. Thrombus inhibition peaks 
within 30 to 60 min of an oral dose, then persists for 
2 to 3 h in rats and about 7 h in rabbits, and correlates 
well with prolongation of the aPTT. 362,363 In rats, the 
intravenous dabigatran dose required to prolong the tail 
bleeding time is 5 to 10 times greater than the maxi-
mally effective antithrombotic dose of 0.1 mg/kg. 363 
 2.2 Pharmacokinetics and Pharmacodynamics 
 Dabigatran etexilate is now formulated as a capsule 
containing multiple small pellets, each of which is 
composed of drug coated on a tartaric acid core to 
create an acid microenvironment that favors drug 
dissolution and preserves gut absorption even when 
the gastric pH is high (solubility is best at a low pH). 364 
Systemic bioavailability of oral dabigatran etexilate 
has been measured at 7.2% in healthy young volun-
teers and estimated at 6% to 7% in healthy older 
subjects. 359,364 Oral bioavailability of the capsules is 
comparable to that of tablets used in the phase 1 
and early phase 2 evaluations. 365,366 Plasma dabigatran 
concentrations peak within 2 hours after a dose of 
dabigatran etexilate and then decrease by  . 70% 
during an initial 4- to 6-h distribution phase that is 
followed by a much slower elimination phase. With 
repeated dosing, the terminal elimination half-life is 
12 to 17 h, the peak and trough concentrations are 
dose-proportional, and it takes 2 to 3 days to reach 
 2.0 Direct Thrombin Inhibitors: 
Dabigatran Etexilate 
 Dabigatran is a selective, reversible, direct throm-
bin inhibitor given as dabigatran etexilate, an orally 
absorbable prodrug, since dabigatran itself is a strongly 
polar molecule that is not absorbed from the gut. 
Phase 3 clinical studies reported to date have evalu-
ated the use of dabigatran etexilate for the prevention 
of VTE after elective total knee or hip arthroplasty, 
for therapy of VTE, and to prevent stroke or systemic 
embolism in nonvalvular AF. The drug is approved in 
many countries for the prevention of VTE in patients 
undergoing total hip or knee replacement surgery 
and in the United States and Canada for the preven-
tion of stroke or systemic embolism in nonvalvular 
AF. Dosing schedules are 150 mg and 220 mg once 
daily when used to prevent VTE (starting with a half 
dose given soon after surgery) and 110 mg and 150 mg 
bid in patients with AF, although only the latter dose 
was approved for this use in the United States. The 
150 mg bid dose was also used for the treatment of 
VTE. Dabigatran etexilate remains under evaluation 
for the secondary prevention of VTE and in the man-
agement of acute coronary syndromes. Melagatran 
(given as its prodrug Ximelagatran) was the fi rst of 
the orally available direct thrombin inhibitors to be 
clinically evaluated and was effective for both the 
prevention and treatment of VTE and in AF but caused 
unacceptable liver toxicity. 353-355 
 2.1 Pharmacology 
 Direct thrombin inhibitors, such as dabigatran, the 
hirudins, and argatroban, do not require a cofactor, 
which differentiates them from the indirect coagula-
tion inhibitors like the heparins, other glycosami-
noglycans, and the synthetic pentasaccharide that 
must form a complex with plasma antithrombin before 
they can accelerate inhibition of thrombin and/or 
factor Xa. 356 Clot-bound thrombin is relatively pro-
tected from heparin-like anticoagulants in vitro but is 
freely accessible to direct thrombin inhibitors. 119 
 Dabigatran (initially referred to as BIBR 953) is 
a small synthetic molecule of 471.5 d with strongly 
basic functional groups that is a concentration depen-
dent, competitive, highly selective and reversible 
direct thrombin inhibitor with a Ki of 4.5   0.2  m M 
(which is comparable with that of melagatran). 357,358 
The inhibitor prevents access to the active site of 
thrombin by forming a salt bridge between its ami-
dine group and Asp 189 and through hydrophobic 
interactions. 357 Like melagatran and argatroban, dab-
igatran is a univalent inhibitor that interacts with the 
active site of thrombin alone, whereas hirudin, lep-
irudin, and desirudin also bind to a substrate recogni-
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and   30 mL/min) than in healthy control subjects. 
The corresponding levels of peak plasma concentra-
tion (Cmax) were 109, 138, and 205 ng/mL, com-
pared with 85 ng/mL when renal function was normal. 
The terminal half-life was doubled to 28 h in severe 
renal failure, from 14 h in control subjects. 370 Strong 
effects of renal function on drug concentrations were 
also demonstrated in patients having a hip or knee 
replacement, in whom dose-effect modeling pre-
dicted a steady-state Cmax of 100 ng/mL during 
bid dosing with 150 mg if the creatinine clearance 
was  . 90 mL/min, increasing to 140, 180, and 240 ng/mL 
as creatinine clearance diminished to 60 to 90, 40 
to 60, and  , 40 mL/min. 366,367 Moderately severe liver 
dysfunction (Child-Pugh classifi cation B) appears to 
have little effect on dabigatran pharmacokinetics, 
since peak plasma concentrations were reduced by 
15% after 150 mg dabigatran etexilate in twelve 
affected subjects, when compared with 12 healthy 
age- and sex-matched control subjects, whereas time 
to Cmax, the elimination half-life, AUC, distribu-
tion volume, and extent of glucuronidation remained 
unchanged. Effects on blood clotting test results were 
similar in the two study groups. 371 The effects on 
blood coagulation tests closely mirror plasma dab-
igatran concentrations. Peak prolongation coincides 
with the Cmax, and clotting times decrease as dabiga-
tran leaves the circulation. Unlike warfarin and other 
vitamin K inhibitors, which have long-lasting effects 
on the INR, the relatively short half-life of dabigatran 
means that time between dosing and blood sampling 
is a critical determinant of drug effect. Effects on the 
aPTT, INR, TCT, and ECT were studied in healthy 
volunteers and in patients having a hip or knee 
replacement. In the placebo-controlled volunteer 
study, wherein healthy men aged 18 to 45 years 
received one dose of 10 to 400 mg dabigatran etexilate 
or eight hourly doses of 50 to 400 mg for 6 days, the 
steady-state levels. The terminal half-life following a 
single dose is about 9 h in healthy volunteers. 359,361,364 
The summary of pharmacokinetic parameters in 
 Table 3 was derived from Stangier. 367 Rapid conver-
sion of dabigatran etexilate to dabigatran ensures that 
plasma concentrations of the etexilate and two inter-
mediate prodrugs barely reach detectable levels. 359 
Approximately 35% of circulating dabigatran is protein-
bound, regardless of concentration. After a 5-mg dose 
of IV dabigatran in healthy volunteers, the distribution 
volume was measured at 69 to 90 L, which exceeds 
the volume of body water, and plasma clearance was 
149 mL/min. 359 About 15% of available dabigatran 
is conjugated to form pharmacologically active but 
unstable glucuronides that account for about 20% of 
the total drug exposure. 359 Eighty-fi ve percent of 
the dose is excreted by renal clearance, almost all as 
unchanged dabigatran. 359 Pharmacokinetic data from 
the phase 2 studies, together with population mod-
eling, predict average steady-state peak and trough 
plasma dabigatran concentrations of 99 and 14 ng/mL 
after daily dosing with 150 mg dabigatran etexilate, 368 
183 and 37 ng/mL after 220 mg/d, 369 and 184 and 
90 ng/mL after 150 mg bid (Table S3). 369 Apart from 
dose, the systemic exposure to dabigatran is related 
to age and renal function. When older but apparently 
healthy volunteers aged 65 to 87 years received 150 mg 
dabigatran etexilate bid, the steady-state area under 
curve (AUC) was 1.7 to 2 times greater than that 
observed in a previous study of younger men aged 
18 to 45 years. The increase in drug exposure was 
explained by reduced renal clearance and was more 
obvious in older women (in whom the AUC was 3% 
to 19% above that in older men). 364,367 In a separate 
parallel group volunteer study, the AUC ¥ after 
150 mg dabigatran etexilate was 1.5, 3.2, and 6.3 
times higher in people with mild, moderate, or severe 
renal impairment (creatinine clearance of 51-80, 31-50, 
 Table 3— [Section 2.2] Pharmacokinetic Characteristics of Dabigatran Etexilate 
Population and Dosage Tmax or Tmax, ss, h
Cmax or 
Cmax, ss, ng/mL/mg
Cmin or 
Cmin, ss, ng/mL/mg
AUC ¥ or 
ss, (ng/h/mL)/mg t 1/2 , h
Healthy adults
 od 1.25-1.5 0.89 5.66 8.13
 bid 1.5-2.0 1.16 0.36 7.4 11.3
 tid 1.68 0.50 7.85 13.7
Healthy elderly
 bid (men) 3.0 1.48 0.52 10.9 12.1
 bid (women) 2.5 1.83 0.52 12.8 13.4
Patients
 od 6.0 a 0.41 a 0.13 6.41 a 
 bid 2.7 1.06 0.45 15.9
The results recorded for bid or tid dosing are at ss. Cmax, Cmin and AUC are normalized to a 1-mg dose of dabigatran etexilate. Results are mean 
or median. AUC  5 area under the curve ; AUC ¥  5 AUC from time zero to infi nity; Cmax  5 peak plasma concentration; Cmin  5 minimum plasma 
concentration; od  5 once daily; ss  5 steady state; tmax  5 time to reach the peak plasma concentration; t 1/2   5 terminal half-life. (Modifi ed with 
permission from Stangier et al. 364 )
 a Measured after fi rst oral dose of dabigatran etexilate following surgery for hip or knee replacement.
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 2.3 Interactions 
 2.3.1 Factors Interfering With Absorption: 
 Absorption of dabigatran etexilate is infl uenced by 
gastric pH as affected by proton pump inhibitors, 
food, the postoperative state, and also by drugs that 
inhibit or induce activity of the cell efflux trans-
porter P-glycoprotein (P-gp). Dabigatran etexilate 
has a low aqueous solubility that is further reduced 
by increased pH, 373 as is observed in patients taking 
the gastric proton pump inhibitor pantoprazole. Twice-
daily pretreatment with 40 mg pantoprazole for 48 h 
in a crossover study reduced geometric mean levels 
of Cmax and AUC after 150 mg dabigatran etexilate 
by 40% and by 32% in healthy male volunteers aged 
18 to 55 years. 365 Bioavailability (steady-state AUC) 
was also reduced by 20% to 40% in a parallel group 
study in which older volunteers, aged   65 years, 
took 40 mg pantoprazole with 150 mg dabigatran 
etexilate bid for 6 days; pantoprazole raised the gastric 
pH from 2.2 to 5.9, and pH correlated with AUC. 
Small corresponding changes in Cmax, ECT, and aPTT 
were not believed to have clinical importance. 364 
 Taking 150 mg dabigatran etexilate after a high-fat, 
high-calorie breakfast prolonged the time taken to 
reach Cmax from 2 h to 4 h in the crossover study 
described above, although Cmax and total drug expo-
sure remained unchanged. 365 Absorption of doses 
taken 4 to 8 h after a hip replacement was slowed and 
reduced, compared with 2 to 10 days later, such that 
time to reach the peak plasma concentration was 
delayed to 6 h and both Cmax and AUC were greatly 
diminished ( Table 3 ); the changes were attributed 
to early effects of surgery on GI motility and gastric 
acidity. 366 
 2.3.2 Other Drug-Drug Interactions:  Important 
drug-drug interactions most often result from changes 
in drug metabolism that are due to induction or 
inhibition of CYP3A4 and other enzymes of the 
microsomal cytochrome P450 complex or from 
changes in drug bioavailability mediated by the 
adenosine diphosphate-dependent cell effl ux trans-
porter, P-glycoprotein (P-gp). 374 Potential drug inter-
actions with dabigatran etexilate have been explored 
in studies in which volunteers received dabigatran 
etexilate together with drugs known to provoke such 
mechanisms. Many drugs may interact through more 
than one pathway. 
 Because cytochrome P450 enzymes have almost 
no role in the metabolism of dabigatran and are not 
affected by dabigatran in vitro, this becomes an 
unlikely mechanism for drug-drug interactions, 359 
and volunteer studies confi rm the lack of a clinically 
important interaction with atorvastatin (a substrate 
for CYP3A4 and substrate/inhibitor of P-gp) and 
diclofenac (a substrate for CYP2C9 and uridine 
drug was given as a dry powder dissolved in dilute 
tartaric acid 361 and caused dose-dependent prolonga-
tions of aPTT, INR, TCT, and ECT. The coagulation 
test results correlated with plasma dabigatran con-
centration, the maximum clotting times coincided 
with Cmax, and effects persisted for 8 h or longer 
except for the aPTT and INR at the lowest doses. The 
peak clotting time ratios after 200 to 400 mg of dab-
igatran etexilate were  . 55 for the TCT,  . 5 for the 
ECT, 1.5 to 1.9 for the INR, and 1.8 to 2.1 for the 
aPTT. The TCT, ECT, and INR increased in linear 
proportion with plasma dabigatran levels, but the 
aPTT concentration-response curve was curvilinear 
and fl attened above concentrations of 200 ng/mL. 361,369 
Plasma dabigatran levels also correlated closely with 
effects on the ECT and aPTT in the BISTRO trial, a 
safety study of dabigatran etexilate in patients having 
an elective hip or knee arthroplasty, wherein esca-
lating doses of dabigatran etexilate were given for 
6 days in tablet form after surgery. The doses were 
12.5 mg rising to 300 mg bid or 150 mg to 300 mg 
once daily. 368 Bid dabigatran etexilate raised the peak 
aPTT and ECT ratios from 1.08 to 1.91 and from 0.96 
to 5.17 as the dose increased from 12.5 mg to 300 mg, 
whereas the mean trough levels of aPTT ratio rose 
from 1.0 to 1.65. 368 Concentration-effect relationships 
were linear for the ECT but nonlinear for the aPTT, 
with better sensitivity and precision for the ECT. 366 A 
nonlinear dose-effect on the aPTT was also found in 
patients with AF taking bid doses of up to 300 mg. 372 
Different aPTT reagents appear to have similar sen-
sitivities to dabigatran, as does the activated clotting 
time. 369 The likely impact of reduced renal function 
on blood clotting test results in patients given 150 mg 
dabigatran etexilate bid was estimated through popu-
lation modeling of data from the BISTRO I study. This 
predicted a maximum aPTT of 47.4 s with normal renal 
function, increasing to 54.2, 61.9, and 78.3 s in patients 
with mild, moderate, or severe reductions in creatinine 
clearance (the corresponding predictions for maximum 
ECT were 55.2, 77.4, 108, and 183 s). 367 The mod-
eling is consistent with results when otherwise healthy 
volunteers with a creatinine clearance  , 30 mL/min 
received a 150-mg dose of dabigatran etexilate: max-
imum aPTT, ECT, INR, and TCT ratios were 3.45, 
3.26, 4.14, and 12.5, compared with 1.85, 1.89, 1.4, and 
6.87 in healthy control subjects. 370 This emphasizes 
the need to avoid dabigatran etexilate in patients with 
severe renal failure and the importance of renal function 
when considering the choice of dosing regimen. It 
remains possible that dabigatran may activate platelets 
in patients with AF, as urinary excretion of 11-
dehydrothromboxane B2 (an end product of throm-
boxane A2 metabolism) was increased by roughly 
20% during 12 weeks of treatment in a dose-ranging 
trial, and that effect was suppressed by aspirin. 372 
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igatran etexilate, there was little effect on the phar-
macokinetics of either drug in a three-way crossover 
study of 23 healthy volunteers aged 18 to 65 years. 378 
 Drug interactions that may change the Cmax and 
AUC of dabigatran have not been correlated with 
clinical outcomes. Very large increases of Cmax and 
AUC, like those of quinidine and systemic ketocon-
azole, are likely to raise the bleeding risk. Moderate 
increases, like those provoked by amiodarone or 
verapamil, may become important if combined with 
old age or reduced renal clearance. The concern about 
strong P-gp inducers like rifampicin is their potential 
to decrease drug exposure and therefore reduce 
effi cacy. 
 2.3.3 Dabigatran Etexilate and Antiplatelet Drugs: 
 The added bleeding risk when platelet function 
inhibitors like aspirin and clopidogrel are taken 
during anticoagulant therapy is compounded for aspi-
rin and other nonsteroidal antiinfl ammatory drugs 
by the increased likelihood of peptic ulceration due 
to interference with prostaglandin-mediated cyto-
protection of the gastrointestinal mucosa. 379 These 
mechanisms are independent from any pharmacoki-
netic drug-drug interactions (none was demonstrated 
between dabigatran etexilate and diclofenac). 376 Aspi-
rin increased the bleeding rate when added to ximel-
agatran in patients with AF and to warfarin in patients 
with AF, a prosthetic heart valve, coronary artery dis-
ease, or peripheral vascular disease. 82,317,380 
 The added effects on bleeding when aspirin is 
combined with dabigatran etexilate were explored in 
the Prevention of Embolic and Thrombotic Events in 
Patients With Persistent Atrial Fibrillation (PETRO) 
trial, a phase 2, parallel-group, randomized, dose-
ranging safety study in 502 patients with nonvalvular 
AF who also had coronary artery disease and/or one 
or more other risk factors for systemic embolism. The 
patients received 12 weeks of treatment with open-
label warfarin alone (target INR 2-3) or with blinded 
50 mg, 150 mg, or 300 mg dabigatran etexilate bid 
plus daily aspirin (81 mg or 325 mg) or a placebo, 
using a 3  3 3 factorial design to allocate study treat-
ments to patient groups of unequal size. Aspirin 
increased the chances of major or clinically signifi -
cant nonmajor bleeding in patients given a supra-
therapeutic dabigatran dose of 300 mg bid, in whom 
the bleeding rate was 20% with an aspirin dose of 
325 mg/d (six of 30), 14.7% if the dose was 81 mg/d 
(fi ve of 34), and 5.7% (six of 105) in patients given the 
aspirin placebo. The trends reached statistical sig-
nifi cance when the two aspirin groups were pooled. 
Bleeding risk was not apparently raised when aspirin 
was added to 50-mg or 150-mg doses of dabigatran, 
but the sample size was too small to exclude clinically 
important effects. 372 
glucuronyltransferase 2b7, and also a substrate and 
weak inhibitor of UGT1A). 367 When 22 volunteers 
aged 43   15 years took 80 mg atorvastatin together 
with 150 mg dabigatran bid for 4 days in an open-
label crossover study, the steady-state AUC of dab-
igatran was reduced by 18%, whereas the Cmax and 
AUC of atorvastatin increased by 15% and 23%. 375 
Cmax and AUC of dabigatran remained unchanged 
in a similar study of 24 volunteers aged 18 to 55 years 
who took one 50-mg dose of diclofenac after 4 days of 
bid dosing with 150 mg dabigatran etexilate, whereas 
Cmax of diclofenac and its main metabolite decreased 
by 11% to 17%. 376 The changes were believed to be 
small and clinically unimportant. 
 In vitro studies fi nd that dabigatran etexilate (but 
not dabigatran) is a substrate for P-glycoprotein 
(P-gp, MDR1) with a medium affi nity when tested 
using the Caco-2 cell-line1, which makes it a poten-
tial target for P-gp-related drug interactions. 377 The 
bioavailability of P-gp substrates like dabigatran may 
be raised or reduced through inhibition or induction 
of P-gp: the P-gp inhibitors include amiodarone, 
verapamil, ketoconazole, quinidine, and clarithromy-
cin, whereas P-gp inducers include rifampicin and 
St. John’s wort ( Hypericum perforatum ). 377 
 In formal interaction studies with amiodarone, a 
fi rst dose of 600 mg raised the AUC and Cmax of 
dabigatran by about 50% and 60%, an interaction 
that may persist for some weeks after stopping amio-
darone due to the long half-life of this drug. 373 The 
effects of verapamil depend on its dosing schedule and 
drug formulation. 373 The fi rst dose of an immediate-
release formulation, when given 1 hour before 150 mg 
dabigatran etexilate, increased the Cmax and AUC 
of dabigatran by about 180% and 150%, but these 
elevations were reduced to about 60% and 50% after 
repeated dosing and to about 90% and 70% when 
taking an extended-release formulation. The inter-
action became negligible (increases of 10% in Cmax 
and 20% for AUC) if verapamil was taken  . 2 h after 
dabigatran etexilate when dabigatran absorption 
was essentially complete. Twice-daily coadminis-
tration of 500 mg clarithromycin increased the AUC 
and Cmax of dabigatran by about 19% and 15%, 
respectively. 
 The strong P-glycoprotein inhibitors quinidine and 
ketoconazole are contraindicated when taking dab-
igatran etexilate because they markedly increase 
exposure to dabigatran. 373 The approved product 
information advises caution when considering coad-
ministration of strong P-gp inducers like rifampicin 
or St. John’s wort, which may signifi cantly decrease 
the Cmax and AUC. 373 
 The P-gp substrate digoxin is used to probe P-gp 
mediated drug-drug interactions. After 4 days of 
dosing with once-daily digoxin plus bid 150 mg dab-
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effective), 383,384,387 but each was less effective after 
knee arthroplasty than 30 mg enoxaparin bid. 385 The 
fi rst dose of dabigatran etexilate was given 1 to 4 h 
after surgery in the comparisons with 40 mg/d enox-
aparin, but delayed until 12 to 24 h after operation in 
the comparison with bid enoxaparin. It is likely the 
bid enoxaparin regimen was superior in part due to 
the higher daily dose (60 mg), but delaying the start 
of dabigatran etexilate after surgery may also have 
contributed to an inferior result. In a subsequent 
comparison, 220 mg/d dabigatran was again “nonin-
ferior” to 40 mg/d enoxaparin in preventing “total 
VTE” after hip arthroplasty but appeared also to be 
more effective in preventing “major VTE” (a com-
posite of proximal DVT, nonfatal PE, and death 
related to VTE). 386 It is now standard practice to start 
anticoagulant treatment after VTE with a heparin 
(unfractionated or low molecular weight) together 
with a VKA, overlap the two drugs for at least 5 days, 
and stop the heparin only after the INR exceeds 2.0 
for  . 2 consecutive days. 
 Dabigatran etexilate was noninferior to warfarin in 
a double-blind, placebo-controlled and randomized, 
phase III comparison in patients with deep leg vein 
thrombosis or PE (the RE-COVER trial) in which 
study treatment began with at least 5 days of an 
approved anticoagulant (predominantly unfractionated 
or low-molecular-weight heparin) plus daily warfarin 
placebo or warfarin. 382 This study design is unlike that 
of other (ongoing) evaluations of new oral anticoagu-
lants for VTE, in which the new oral anticoagulant is 
given alone from the initiation of therapy. The pri-
mary measure of effi cacy was the incidence of symp-
tomatic and confi rmed nonfatal recurrence, or death 
related to VTE. Randomization in RE-COVER was 
substratifi ed for a clinical presentation with symp-
tomatic PE (31% of the total) and subgroup analysis 
suggests this presentation had little or no effect on 
the relative effi cacy of dabigatran. Masking was pre-
served by using coded POC machines to generate a 
real or sham INR. Once this exceeded 2.0 for 2 con-
secutive days, they received dabigatran etexilate 
150 mg or its placebo bid (ie, they continued warfarin 
or started dabigatran). Hence, all patients received at 
least 5 days of initial treatment with a heparin. How-
ever, the median total duration of parenteral therapy 
before starting dabigatran was 9 days in both of the 
RE-COVER study groups, which seems longer than 
the usual clinical practice. INR was within its tar-
geted range of 2.0 to 3.0 for 60% of study time in the 
warfarin-treated patients. 
 VKAs are highly effective in preventing embolic 
stroke from AF, achieving risk reductions of almost 
70% when compared with placebo and about 50% 
when compared with aspirin 387 ; their most feared 
complication is intracranial bleeding, with an added 
 Low doses of aspirin (  100 mg/d) were permitted 
in the Randomized Evaluation of Long-term Anti-
coagulant Therapy (RE-LY) (nonvalvular AF) and 
Dabigatran in the Treatment of Venous Thrombo-
embolism (RE-MEDY) (VTE) phase 3 studies of 
dabigatran etexilate, which compared bid doses of 
110 mg and/or 150 mg with warfarin, but subgroup 
analyses of bleeding risk are not yet available. 381,382 
Product information recommends against the com-
bination of dabigatran etexilate with clopidogrel and 
other thienopyridines, given alone or as dual antiplate-
let therapy with aspirin. 
 2.4 Antithrombotic Effects:  A number of recent 
phase III clinical trials have evaluated the use of dab-
igatran etexilate for the prevention and treatment of 
VTE and to prevent systemic embolism in nonvalvu-
lar AF. A phase II study explored its dose-response in 
acute coronary syndromes. 
 The effi cacy and safety of anticoagulant prophy-
laxis for VTE depends in any given patient popula-
tion on the dose, timing, duration, and choice of drug 
therapy (ie, on the treatment regimen as well as the 
therapeutic agent). The VTE prevention trials of 
dabigatran etexilate have evaluated two once-daily 
dabigatran dosing regimens in patients having elec-
tive hip or knee arthroplasty: 150 mg/d or 220 mg/d, 
beginning soon after surgery with a half-dose of 
75 mg or 110 mg. In addition, these two dabigatran 
regimens were compared with one of two standard 
enoxaparin prophylaxis regimens: 40 mg/d starting on 
the evening before surgery, or 30 mg bid starting 
12 to 24 h after surgery (worldwide, these are the 
low-molecular-weight heparin prophylaxis regimens 
most widely used for joint surgery; both are accepted 
as standard clinical practice). Two of the trials com-
pared both of these dabigatran regimens with the 
40 mg/d schedule of enoxaparin in hip or knee 
arthroplasty, 383,384 one compared both of the dabiga-
tran regimens with 30 mg enoxaparin bid after knee 
arthroplasty, 385 and one compared only the 220 mg/d 
dabigatran etexilate regimen with enoxaparin 40 mg/d 
in hip arthroplasty. 386 
 In all prophylaxis studies, the primary measure of 
treatment effectiveness was the rate of “total VTE” 
(a composite of subclinical deep leg vein thrombosis 
detected with routine bilateral ascending venography 
done at the end of treatment, confi rmed symptom-
atic DVT or pulmonary embolism (PE), and death 
from any cause), an outcome that could be evaluated 
in 73% to 78% of patients. All recorded the presence 
of major bleeding, clinically relevant nonmajor bleed-
ing, and any adjudicated bleeding. 
 The two dabigatran prophylaxis regimens were 
“noninferior” to enoxaparin 40 mg/d in hip arthro-
plasty and in knee arthroplasty (ie, statistically no less 
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presence of dabigatran. TCT tests are available rou-
tinely in many laboratories. 
 2.6 Practical Issues Related to Initiation 
and Maintenance 
 Unlike other new oral anticoagulants, dabigatran 
etexilate offers a choice between higher and lower 
dosing regimens, since the schedules evaluated in 
phase III clinical studies to date were 150 mg and 
220 mg once daily when used to prevent postopera-
tive VTE, 150 mg bid for the treatment of VTE, and 
110 mg and 150 mg bid in patients with AF. 
 Dose was important during long-term therapy of 
patients with AF, in whom 150 mg bid was superior 
to warfarin and 110 mg bid was noninferior, whereas 
the rates of major bleeding were similar with 150 mg 
dabigatran and warfarin but signifi cantly less with 
110 mg dabigatran. However, only the 150-mg dose 
was approved in the United States, whereas in Can-
ada both doses are approved. By contrast, there was 
less apparent effect of prophylactic dosing level on 
effi cacy or the likelihood of surgical bleeding after 
major joint replacement, when compared with 40 mg/d 
enoxaparin. 
 Subgroup analyses of large clinical studies have 
provided little evidence to date for clinically impor-
tant effects of age, gender, or renal function on effi -
cacy or safety within any dosing level. Without such 
information, the choice between available dosing 
regimens must rest on individual decisions about the 
preferred balance between effi cacy and bleeding risk 
and on extrapolations about that risk from pharmaco-
kinetics of this predominantly renally excreted drug. 
For example, a lower dose may be preferred for 
elderly patients with a mild to moderate decrease of 
renal function. In addition, the choice will be infl u-
enced by known drug interactions (see section 2.3 
“Interactions” ). 
 At this time, the only product information approved 
by European Medicines Agency (EMA) and other 
regulators is for prophylactic dosing with dabigatran 
etexilate. Based on clinical study results and pharma-
cokinetic evidence, EMA recommends a standard 
daily dose of 220 mg, reduced to 150 mg if patients are 
aged  . 75 years, have a creatinine clearance between 
30 and 50 mL/min, or need treatment with verapamil 
or amiodarone. Ensuring compliance with continued 
dosing will be a concern for dabigatran etexilate, as 
it is with any chronic therapy that does not require 
repeated measurement of drug effect. 
 2.7 Adverse Events 
 2.7.1 Bleeding Events:  The major potential haz-
ard from dabigatran etexilate is bleeding. After an 
risk of approximately 0.2% per annum during ongoing 
warfarin treatment. 388 
 Dabigatran dosing regimens of 110 mg and 150 mg 
bid were compared double-blind with open-label 
warfarin (target INR, 2.0-3.0) in the RE-LY trial 
where patients with nonvalvular AF received study 
treatment of at least 1 year and median of 2 years, 
and the primary study outcome was ischemic stroke 
or systemic embolism. 381 On average, the INR in 
patients taking warfarin was within its target range of 
2.0 to 3.0 for 64% of study time. Both effi cacy and 
bleeding risk of dabigatran etexilate depended on 
the dose. Annual rates of ischemic stroke or embo-
lism were 1.69% with warfarin, 1.53% with 110 mg 
dabigatran bid (noninferior), and 1.11% with 150 mg 
dabigatran ( P  , .001 relative to warfarin,  P  5 .005 
relative to 110 mg dabigatran). The annual incidence 
of major bleeding was similar, with 150 mg dabiga-
tran and warfarin, but signifi cantly less with 110 mg 
dabigatran (see section 2.6 “Practical Issues Related 
to Initiation and Maintenance” ). A striking result was 
the reduced frequency of hemorrhagic stroke with 
dabigatran compared with warfarin ( P  , .001), regard-
less of dabigatran dose. 
 2.5 Monitoring Anticoagulant Intensity 
 Ex vivo effects on laboratory tests after taking 
dabigatran etexilate were summarized in section 2.2 
“Pharmacokinetics and Pharmacodynamics.” Simple 
widely used coagulation tests have limitations for 
measuring dabigatran effect: the PT and aPTT are 
relatively insensitive, the relation between aPTT and 
dabigatran concentration is nonlinear, and the usual 
form of TCT is oversensitive. Most promising is the 
ECT, which has a linear dose-response throughout 
the range of concentrations expected during pro-
phylaxis or therapy; however, this test is not readily 
available. 369 
 There is no evidence relevant to the possible clin-
ical benefi ts from laboratory testing, since the phase 
3 studies evaluated fi xed doses and their reports 
have not examined clinical outcomes in relation to 
drug levels or clotting test results. The intent has 
been to recommend standard doses for most patients; 
although fi rst principles suggest that laboratory-
assisted dose adjustment of this mainly renally excreted 
drug could add clinical value in selected populations, 
as in elderly subjects with reduced renal function, 389 
it seems unlikely that routine monitoring would yield 
any wide clinical benefi t. 390 Perhaps the most likely 
role for laboratory testing may be in treated patients 
who bleed or develop thrombosis, need an acute 
invasive procedure, or could have taken an overdose. 
In the setting of major bleeding, or if urgent or emer-
gent surgery is required, a normal TCT rules out the 
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 It is essential to exclude liver toxicity when evalu-
ating new oral anticoagulants, especially because the 
fi rst orally available direct thrombin inhibitor (ximel-
agatran) caused unacceptable hepatic toxicity that 
remains unexplained. About 0.5% of the patients 
treated with ximelagatran for  . 35 days developed 
laboratory evidence of severe liver injury: a greater 
than threefold elevation of serum alanine transami-
nase level plus a greater than twofold increase in bil-
irubin concentration, compared with upper normal 
limits. 355,391 In one 35-day VTE prevention study, 
severe hepatic injury with onset after the end of drug 
exposure was not predicted by regular liver enzyme 
monitoring during therapy. 392 It has been estimated 
that ximelagatran may have caused or contributed to 
fatal liver damage in about 1 in 2,000 patients. 355 No 
dabigatran study to date has recorded a dispropor-
tionate increase of liver enzyme levels or clinically 
signifi cant liver disease as an adverse effect. 
 In some ximelagatran studies, short- or long-term 
treatment was also associated with trends or a statis-
tically signifi cant excess of adverse events related 
to coronary artery disease. 355 This raised concerns 
that other new oral anticoagulants might increase the 
risk from acute cardiac events. Adjudicated coronary 
events (unstable angina, myocardial infarction, car-
diac death) were rare and evenly distributed between 
study groups in the orthopedic surgery studies of 
dabigatran etexilate and in the RE-COVER trial, but 
the RE-LY trial reported an excess of myocardial 
infarction among the patients treated with dabigatran. 
The relative risks, compared with warfarin, were 1.35 
( P  5 .07) with 110 mg and 1.38 ( P  5 .048) with 150 mg 
dabigatran (the corresponding absolute risks were 
0.53%, 0.72%, and 0.74% per annum). 381 There are 
no ready explanations (although indirect evidence 
of platelet activation by dabigatran was reported from 
the PETRO study). 372 
 2.8 Reversal of Drug Effect 
 There is insuffi cient clinical experience to fi rmly 
guide the management of major bleeding, suspected 
overdose, urgently needed surgery, or urgent inva-
sive diagnostic or therapeutic procedures in patients 
who are taking this new drug. Pharmacokinetic mod-
eling does, however, indicate how long it takes for 
drug effects to dissipate after stopping dabigatran 
etexilate before an elective intervention, although 
conclusions about the time taken before a return to 
normal hemostasis remain tentative pending well-
documented information about clinical outcomes. 
 The half-life of dabigatran suggests that drug levels 
and drug effects should decrease by about 50% at 
12 to 18 h after the most recent dose, and the trough 
levels to 25% of their previous steady state by 24 h 
elective hip or knee replacement, the risks of major 
bleeding were small during VTE prophylaxis with 
dabigatran etexilate and similar to those with pro-
phylactic enoxaparin. The rates were 0.6% to 1.3% 
in patients given 150 mg/d and 0.6% to 2.0% when 
the dose was 220 mg/d. These compared with 1.3% 
to 1.6% with 40 mg/d of enoxaparin and 1.4% with 
30 mg of enoxaparin given bid. About 90% of the 
bleeding events were related to the surgical wound. 
 Bleeding risk during 6 months of treatment after 
VTE was less with 150 mg dabigatran bid than with 
warfarin (target INR, 2.0-3.0). The 6-month rate of 
“any bleeding” was reduced from 21.9% with warfa-
rin to 16.1% (relative risk, 0.71; 95% CI, 0.59-0.85), 
and that of “major or clinically relevant but non-
major” bleeding was diminished from 8.8% to 5.6% 
(relative risk, 0.63; 95% CI, 0.47-0.84;  P  5 .002). 
Major bleeding was infrequent (1.9% with warfarin 
and 1.6% with dabigatran). 382 
 As indicated earlier, the bleeding risk was dose 
dependent in the RE-LY study of patients with AF: 
the annual incidence of major bleeding was 3.4% in 
patients taking warfarin, 3.1% with 150 mg bid dab-
igatran (relative risk, 0.93;  P  5 .31), and 2.7% if 
the dose was 110 mg (relative risk, 0.80; 95% CI, 
0.69-0.93;  P  5 .003); the  P value of the difference 
between dabigatran dosing groups almost reached the 
conventional level for statistical signifi cance ( P  5 .052). 
Both dabigatran regimens reduced the likelihood of 
intracranial bleeding by more than one-half compared 
with warfarin (annual incidence was 0.74% with war-
farin, 0.30% with 150 mg dabigatran [ P  , .001] and 
0.23% with 110 mg dabigatran [ P  , .001]), whereas 
annual rates of major extracranial bleeding were little 
different between the study groups. 381 
 Dabigatran etexilate does cause a dose-dependent 
increase in the incidence of major GI bleeding. This 
was a statistically signifi cant effect in the RE-LY 
study; annual rates were 1.02% with warfarin, 1.51% 
with 150 mg dabigatran ( P  , .001 compared with warfa-
rin), and 1.12% with 110 mg dabigatran. 381 An excess 
risk was also reported in the RE-COVER trial, in 
which more patients treated with bid 150 mg dab-
igatran etexilate had GI bleeding (53 events vs 35 with 
warfarin). 382 
 2.7.2 Nonhemorrhagic Adverse Events:  Dys-
pepsia is a consistently reported adverse effect of 
dabigatran etexilate. In the RE-LY study, in which 
warfarin was open label, 11.8% and 11.3% of patients 
given 110 mg or 150 mg dabigatran complained of 
dyspepsia compared with 5.8% of patients taking 
warfarin. 381 Fewer patients reported dyspepsia in 
the wholly double-blind RE-COVER trial: 2.9% 
with 150 mg dabigatran bid, and 0.6% with warfarin 
( P  , .001). 382 
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once daily in major orthopedic surgery and 20 mg once 
daily in the long-term secondary prevention of VTE. 
 3.1 Pharmacology 
 Rivaroxaban is a selective and competitive active-
site-directed, reversible factor Xa inhibitor with selec-
tivity for factor Xa that is  . 10,000-fold that for other 
trypsin-like serine proteases. 397 Rivaroxaban acts 
through electrostatic interaction with Asp189 in the 
S1 pocket of factor Xa. This interaction involves the 
chlorine substituent of the chlorothiophene moiety, 
which interacts with the aromatic ring of Tyr228 at 
the bottom of the S1 pocket. 398 Because rivaroxaban 
is a nonbasic, small molecule (the molecular weight 
is 436 g/mol) it can inhibit not only free factor Xa 
but also prothrombinase complex and clot-associated 
factor Xa. 399,400 This range of activities is unique to 
small, direct inhibitors because the factor Xa incor-
porated in the prothrombinase complex is protected 
from inhibition by antithrombin and by antithrom-
bin-dependent anticoagulants. 
 Rivaroxaban is minimally soluble in organic solvents 
and nearly insoluble in water. 398 Binding to plasma 
proteins, mainly albumin, ranges between 92% and 
95%. 398 Rivaroxaban is metabolized via oxidative 
and hydrolytic pathways involving different classes 
of enzymes. In humans, CYP3A4 and CYP2J2 are 
the two enzymes responsible for its oxidative metab-
olism and contribute to a similar extent. 401 About 
66% of rivaroxaban is excreted via the kidneys 
(36% unchanged), and 28% is excreted in the feces 
(7% unchanged). 
 Inhibition of factor Xa activity by rivaroxaban is 
highly dependent on the concentration of the drug. 
Rivaroxaban induces prolongation of the PT, aPTT, 
and heparin clotting time, among other tests. 399,402 
On the other hand, rivaroxaban does not affect the 
bleeding time or platelet aggregation. 399,403 Animal 
models demonstrated dose-dependent reduction of 
thrombus formation by rivaroxaban. 399 
 3.2 Pharmacokinetics and Pharmacodynamics 
 In healthy men aged 19 to 45 years, single doses 
of rivaroxaban administered after a fasting period of 
10 h produced a median inhibition of factor Xa 
activity that ranged from 20% with the 5-mg dose to 
61% with the maximum dose of 80 mg. 404 No signifi -
cant inhibition was observed with doses of  , 5 mg. 
The maximum inhibition of factor Xa activity occurred 
between 1 and 4 h after drug administration, and the 
half-life of the biologic effect was 6 to 7 h. Factor Xa 
activities did not return to normal until after 24 h, 
when doses  . 5 mg were administered. 404 The effect 
on PT prolongation had a similar profi le, as did effects 
after stopping dabigatran etexilate, so long as creati-
nine clearance exceeds 50 mL/min. The level at which 
it is safe to undertake surgery or an invasive proce-
dure is unknown. Moderately severe renal dysfunc-
tion (creatinine clearance of 30-50 mL/min) extends 
the half-life to about 18 h, in which case, or if the 
surgical bleeding risk is critically high (as with intra-
cranial surgery), it may be better to delay elective 
procedures until 2 to 4 days after stopping the drug. 
Measuring the TCT or aPTT should help to estimate 
the residual level of dabigatran. 369 
 In addition to immediately stopping drug adminis-
tration, the clinical management of major bleeding 
would require early volume and RBC replacement, 
urgent assessment for cause, and any local measures 
that may be required until the bleeding stops (pres-
sure, cautery, suture, or other interventions). It is 
believed that maintaining an adequate diuresis could 
help to protect the renal excretion of dabigatran. 
Although product information for dabigatran etexi-
late mentions the use of fresh frozen plasma to help 
control bleeding, this seems unlikely to infl uence 
the drug effects. Thus plasma should only be admin-
istered in the setting of a documented dilutional 
coagulopathy. 
 Dabigatran has no antidote, and the management of 
life-threatening bleeding remains empirical. Indirect 
evidence from animal models and in vitro studies sug-
gests that recombinant factor VIIa or a prothrombin 
complex concentrate may bypass the anticoagulant 
effects of high dabigatran concentrations. 369 It may 
also be relevant that hemodialysis removed 62% of 
circulating dabigatran within 2 h and 68% within 4 h 
in an open-label study of 12 subjects with end-stage 
renal failure who received 50 mg dabigatran 
etexilate. 369,370 In vitro mixing experiments suggest 
that early administration of activated charcoal might 
reduce the absorption of dabigatran etexilate. 369 
 3.0 Direct Factor Xa Inhibitors: Rivaroxaban 
 Rivaroxaban is a direct factor Xa inhibitor and is 
currently approved in many countries, including the 
United States, for the prevention of VTE in patients 
undergoing total hip or knee replacement surgery. 
The drug is undergoing an extensive clinical develop-
ment program in other clinical settings, including the 
treatment of VTE and the prevention of acute ische-
mic stroke in patients with AF. In phase III clinical 
trials, rivaroxaban was found to be more effective 
than the low-molecular-weight heparin enoxaparin in 
preventing VTE after total hip or knee replacement 
surgery 393-396 and more effective than placebo when 
given to patients with previous DVT or PE after an 
initial 6- to 12-month course of standard oral antico-
agulant treatment. The doses evaluated were 10 mg 
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approximately 4 to 6 h on the fi rst day and of approx-
imately 6 to 9 h on the last day of treatment. The 
correlation between plasma concentrations of rivar-
oxaban and inhibition of factor Xa activity or PT pro-
longation was linear, with an  r of 0.950 and 0.958, 
respectively. 405 
 Data from this study were later used for population 
modeling that would predict the behavior of the 
drug in patients. 406 Results of this model showed that 
pharmacokinetics of rivaroxaban were linear and dose 
proportional up to the 30-mg dose and confi rmed a 
strong linear correlation between plasma concentra-
tion and pharmacodynamic parameters. 
 The pharmacokinetics and pharmacodynamics 
of rivaroxaban were also measured in a population 
of healthy elderly subjects and in patients with 
an extremely low or extremely high body weight 
( Table 4 ). 407,408 In the fi rst study, healthy subjects 
aged   60 years received daily doses ranging between 
30 mg and 50 mg after a standard breakfast. 407 It was 
intended to assess even higher doses of up to 80 mg, 
but dose escalation was stopped prematurely because 
of an apparent ceiling effect in pharmacokinetic and 
pharmacodynamic variables. Maximum inhibition of 
factor Xa activity ranged from 68.4% after the 30-mg 
dose to 75.3% and 74.5% after the doses of 40 mg 
and 50 mg, respectively, and occurred 2 to 4 h after 
administration. No gender differences were observed. 
PT prolongation was also greater with the 40-mg 
dose than with the 30-mg dose, and was not different 
between the two highest doses, with a maximum 
effect 2 to 3 h after drug administration. Similar 
profi les were documented for the aPTT and the 
HEPTEST. Maximum concentration of rivaroxaban was 
reached after 4 h in all dose groups, and the half-life 
on the aPTT and HEPTEST (a low-molecular-weight 
heparin activity assay). Conversely, rivaroxaban had 
no effect on thrombin and antithrombin activity. 404 
Peak plasma concentration of the drug occurred at 
2 h, and the terminal half-life was between 7 and 17 h. 
At doses  . 10 mg, the increases in peak plasma con-
centration and AUC were less than dose proportional. 
Approximately 40% of the administered dose was 
excreted unchanged via the kidneys when the 1.25-mg 
dose was administered; this proportion decreased 
to 10% with the highest doses tested (ie, 60-80 mg). 
Finally, inhibition of factor Xa activity and PT prolon-
gation correlated strongly with plasma concentrations 
( r  5 0.949 and  r  5 0.935, respectively). 404 When mul-
tiple doses were administered at mealtime in healthy 
male subjects aged 20 to 45 years, the maximum inhi-
bition of factor Xa activity was documented after 
approximately 3 h and it was dose dependent, ranging 
from 22% after 5 mg to 68% after 30 mg ( Table 4 ). 405 
Inhibition was maintained for 8 to 12 h after 5-mg 
doses and for approximately 12 h after doses of 10 mg 
to 30 mg. Daily rivaroxaban doses did not cause a fur-
ther increase in the maximum inhibition of factor Xa 
activity. A very similar pattern was observed with PT, 
aPTT, and HEPTEST prolongation, which was dose 
dependent for all tests, reached maximum levels after 
1 to 4 h, and was comparable after the fi rst and last 
administered dose. 405 When inhibition of factor Xa 
activity was compared after once, twice, or three 
times daily administration of the 5-mg dose, there 
was no detectable difference between the maximum 
effect on the fi rst and the last day of administration. 
The plasma concentrations of rivaroxaban were also 
dose dependent, with maximum concentrations at 
3 to 4 h for all doses and regimens and a half-life of 
 Table 4— [Section 3.2] Pharmacokinetic Characteristics of Rivaroxaban 402,404,405 
Population and Dosage Tmax, h, median Cmax,  m g/L AUC or AUC t ,  m g·h/L t 1/2 , h
Healthy adults a 
 5 mg od 3.00 76.4 (18.3) 505.5 (19.7) 8.4 (32.6)
 5 mg bid 3.00 85.3 (17.7) 458.5 (13.1) 7.0 (27.8)
 5 mg tid 2.00 123.8 (19.7) 557.3 (20.4) 5.8 (35.5)
 10 mg bid 2.98 158.0 (18.8) 863.8 (18.6) 7.6 (26.7)
 20 mg bid 2.50 318.1 (18.7) 1,903.0 (24.5) 8.0 (40.7)
 30 mg bid 3.02 451.9 (10.5) 2,728.0 (14.6) 9.2 (64.1)
Healthy elderly
 30 mg single dose 4.0 392.0 (23.0) 3,531.0 (20.0) 11.7 (63.7)
 40 mg single dose 4.0 461.0 (16.8) 4,385.0 (24.1) 13.3 (31.9)
 50 mg single dose 4.0 437.0 (32.0) 4,496.0 (33.9) 11.9 (47.8)
Body weight b 
   50 kg women only 4.00 178.1 (16.6) 1,172.0 (22.0) 9.6 (36.7)
 70-80 kg 3.50 143.4 (26.5) 1,029 (20.1) 7.2 (42.1)
  . 120 kg 4.00 149.0 (20.4) 1,155 (15.6) 7.3 (25.4)
Data are presented as geometric mean (geometric coeffi cient of variation). AUC t  5 AUC during a dosage interval at steady state. See Table 3 for 
expansion of other abbreviations .
 a Multiple doses.
 b 10 mg single dose.
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dependent. Between 14% and 31% of rivaroxaban 
was excreted unchanged via the kidneys. The clear-
ance of the drug was consistently affected only by renal 
function, with a creatinine clearance of 30 mL/min 
resulting in a 15% to 35% higher drug exposure in 
these two trials. 412 Based on the results of subsequent 
simulations of various scenarios for patients with dif-
ferent extremes of covariates, it was estimated that 
plasma concentrations of rivaroxaban would have 
exceeded the 90% CI of the average patient only in a 
90-year-old patient weighing 30 kg, suggesting that 
one dose of the drug could be administered to all 
patients regardless of their age, gender, and body 
weight. The second study compared data from two 
phase II clinical trials, both carried out in patients 
undergoing total hip replacement surgery, one assess-
ing bid doses and the other assessing single daily 
doses. 413 Overall, the pharmacokinetics were similar 
after once-daily or bid dosing, since only the steady-
state area under the plasma concentration-time curve 
over 24 h was higher with once-daily doses than with 
bid doses 413 (Table S4). PT prolongation strongly cor-
related with plasma concentrations when rivaroxaban 
was given once daily or bid. 413 Simulations of plasma 
concentration expected after a 10-mg once-daily 
dose in model subjects with extreme demographic 
characteristics showed that plasma concentration-
time profi les would fall within the predicted 90% CI 
of the average patient. 
 3.3 Interactions 
 3.3.1 Drugs:  In humans, CYP3A4 plays a pivotal 
role in the oxidative metabolism of rivaroxaban. 401 
Drugs that inhibit or induce CYP3A4 have the poten-
tial to interact with rivaroxaban. However, only drugs 
that act as strong inhibitors of both CYP3A4 and of 
P-glycoprotein, a transporter protein of which rivar-
oxaban is a substrate, have been shown to cause 
important reduction of the clearance of the drug, 
thus provoking a signifi cant increase in plasma con-
centrations. These drugs include azole antimycotics 
and HIV protease inhibitors. The concomitant ad-
ministration of rivaroxaban with ketoconazole 400 mg 
once daily or with ritonavir 600 mg bid resulted in 
an approximately 2.5-fold increase in the mean AUC 
and 1.7-fold increase in the mean Cmax of rivaroxa-
ban, together with signifi cantly increased effects 
on clotting tests. 414 Thus, the use of rivaroxaban in 
patients receiving ketoconazole, itraconazole, vori-
conazole, and posaconazole or any HIV protease 
inhibitor is currently not recommended. 414 Rivaroxa-
ban should be used with caution when given together 
with other drugs that strongly inhibit only CYP3A4 or 
only P-glycoprotein. These drugs include clarithro-
mycin, which at the dose of 500 mg bid leads to a 
ranged between 12 and 13 h ( Table 4 ). Excretion via 
the kidneys was similar among the dosing groups: 
although women had higher drug concentrations than 
men after the 30-mg and 40-mg doses, the authors 
considered that none of the pharmacokinetic param-
eters showed clinically signifi cant differences between 
females and males. Finally, the slopes of correlations 
between plasma concentrations of rivaroxaban and 
clotting tests were similar in this population of healthy 
elderly subjects and the population of healthy young 
men enrolled in a previous study. 407 Other studies 
have subsequently confi rmed the absence of gender-
based differences in the pharmacokinetics of rivar-
oxaban. 409 Pharmacokinetics and pharmacodynamics 
of rivaroxaban in young and elderly Chinese men and 
women are comparable to those previously reported 
in studies of healthy whites . 410,411 
 The effects of extreme body weight on a single 
10-mg daily dose of rivaroxaban were assessed in a 
study carried out in men and women aged 18 to 
55 years weighing   50 kg, between 70 and 80 kg, 
or  . 120 kg ( Table 4 ). 408 Peak plasma concentrations 
were higher in the low body weight group than in the 
other two groups, with a Cmax value that was signifi -
cantly increased by 24% as compared with the nor-
mal body weight group. On the other hand, there was 
no difference in plasma concentrations between sub-
jects with a normal or high body weight, and the AUC 
was similar among all three groups. The half-life of 
rivaroxaban was increased by 2 h in the low body 
weight group. Inhibition of factor Xa activity was sim-
ilar in the three groups, with a maximum effect that 
occurred after 3 to 4 h and was slightly lower in the 
group of patients weighing  . 120 kg than in the other 
two groups. The maximum prolongation of PT, aPTT, 
and the HEPTEST decreased signifi cantly with increas-
ing body weight, although overall all these changes 
were small. 408 
 Finally, to defi ne the pharmacokinetics and pharma-
codynamics of rivaroxaban in a population of patients 
undergoing major orthopedic surgery, blood samples 
were obtained from patients enrolled in phase II ran-
domized trials. 412,413 The fi rst study analyzed data 
from two trials that assessed bid doses of rivaroxaban 
ranging from 2.5 mg to 30 mg administered at meal-
times. 412 Exclusion criteria from these trials were body 
weight  , 45 kg, creatinine clearance  , 30 mL/min, 
and severely impaired hepatic function. The authors 
found substantial variability in the pharmacokinetics 
of rivaroxaban on the fi rst postoperative day for all 
doses, possibly attributed to the presence of “slow” 
and “fast” absorbers. Overall, absorption was fast, 
with a Cmax within 1 to 2 h. Absorption status was 
unrelated to gender, food, anesthesia, or the use of 
comedications. The variability at steady state was only 
moderate, and the increase of exposure was dose 
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drugs that alter the gastric pH, such as the histamine H2 
antagonist ranitidine or the antacid aluminum-
magnesium hydroxide, had no effect on the plasma con-
centrations or pharmacodynamics of rivaroxaban. 418 
 3.3.3 Environmental Factors:  The effect of food 
on the absorption of rivaroxaban was tested in healthy 
male subjects aged 18 to 45 years. 418 After a single 
dose of 5 mg, the absorption of rivaroxaban was found 
to be slower in the fed state than the fasting state, 
with a delay in the median time to reach the peak 
plasma concentration from 2.75 h to 4.0 h. The AUC 
and the Cmax both increased with the concomitant 
administration of food, by 28% and 41%, whereas 
the terminal half-life remained unchanged. The fed 
state increased the time to maximum prolongation 
of the PT and maximum inhibition of factor Xa activ-
ity and also the maximum effect on these clotting 
tests. Thus, absorption of rivaroxaban was moderately 
increased after the administration of food, with a 
resulting increase in pharmacokinetic and pharmaco-
dynamic parameters. In addition, concomitant food 
intake reduced interindividual variability, whereas 
elimination remained unchanged. No pharmacokinetic 
differences were documented when high-fat, high-
calorie meals were compared with high-carbohydrate 
meals. These food effects have been attributed to a 
prolonged length of stay in the stomach that is pos-
sibly related to the lipophilicity and limited aqueous 
solubility of the drug. 418 
 3.4 Antithrombotic Effect 
 Rivaroxaban acts as a competitive inhibitor of the 
amidolytic activity of factor Xa. In vitro, the inhibitory 
effect is concentration dependent, with an inhibitory 
constant against factor Xa of 0.4   0.02 nM. 399 The 
selectivity of rivaroxaban for factor Xa is 10,000-fold 
greater than for other serine proteases, including 
factor Va, factor IXa, factor XIa, thrombin, and acti-
vated protein C. The onset of action is rapid and 
reversible, as shown by the kinetic association rate 
constant of 1.7  3 10 7 mol/L –1 /s –1 and kinetic dissoci-
ation rate constant of 5  3 10  2 3 /s –1 . 419 The inhibitory 
effect is maintained when factor Xa is complexed 
with factor Va and Ca 2 1  on a phospholipid membrane 
(prothrombinase bound) as shown by a concentra-
tion-dependent inhibition of thrombin generation 399 
and also when factor Xa is bound to the clot. 420 
 In plasma, endogenous human factor Xa is inhib-
ited by rivaroxaban to cause dose-dependent prolon-
gation of both the PT and aPTT, with the PT being 
more sensitive than the aPTT. 399 In whole blood 
and in platelet-rich plasma, rivaroxaban has a dose-
dependent effect in prolonging the initiation phase 
of thrombin generation after activation of the tissue 
1.5-fold increase in the mean AUC and to a 1.4-fold 
increase in the Cmax of the drug, and erythromycin, 
which at the dose of 500 mg three times daily causes 
a 1.3-fold increase in both the AUC and the Cmax. 414 
On the other hand, reduced plasma concentrations of 
rivaroxaban can occur when strong CYP3A4 inducers 
are coadministered. These include rifampicin (which 
causes a 50% decrease in the AUC), phenytoin, car-
bamazepine, phenobarbital, or St. John’s wort. 414 The 
concomitant administration of rivaroxaban with sub-
strates of either CYP3A4 or P-glycoprotein, such as 
atorvastatin, digoxin, or midazolam, did not result in 
clinically relevant interactions. 415,416 
 The concomitant administration of rivaroxaban and 
aspirin was tested in a randomized, two-way cross-
over study. 403 Healthy men aged between 18 and 
55 years were randomized to receive aspirin alone at 
the dose of 500 mg on the fi rst day and 100 mg on 
the second day, rivaroxaban alone at the dose of 
15 mg, or aspirin and rivaroxaban at the same dos-
ages. Patients receiving rivaroxaban alone were sub-
sequently treated with rivaroxaban and aspirin and 
vice versa. Maximum levels of inhibition of factor Xa 
activity and maximum prolongation of the PT, aPTT, 
and the HEPTEST were similar in patients treated 
with rivaroxaban alone and in patients treated with 
rivaroxaban plus aspirin. Collagen-stimulated platelet 
aggregation was inhibited in the aspirin-alone group 
and in the aspirin plus rivaroxaban group but not in 
the rivaroxaban-alone group. Inhibition of platelet 
aggregation with aspirin was 89.3% greater than with 
rivaroxaban alone, and with aspirin plus rivaroxaban 
it was 97.4% greater than with rivaroxaban alone. 
Bleeding time was not affected by rivaroxaban alone, 
but was prolonged to 1.46 times the baseline by aspi-
rin alone and to 1.96 times the baseline by adding 
aspirin to rivaroxaban. The combination of aspirin 
with rivaroxaban prolonged bleeding time more than 
aspirin alone. Pharmacokinetic parameters of rivar-
oxaban were not altered by the coadministration of 
aspirin. 
 The concomitant administration of rivaroxaban and 
a nonsteroidal antiinfl ammatory drug was also tested 
in a randomized two-way crossover study. 417 Healthy 
men aged between 18 and 45 years were randomized 
to receive 15 mg of rivaroxaban alone or 15 mg rivar-
oxaban plus naproxen 500 mg. After 14 days all sub-
jects crossed over. Maximum inhibition of factor Xa 
activity and maximum prolongations of the PT, aPTT, 
and HEPTEST were similar between the two groups. 
Bleeding time was signifi cantly increased by the com-
bined use of rivaroxaban and naproxen as compared 
with rivaroxaban alone. Plasma concentrations of 
rivaroxaban were slightly increased, by 10% for both 
the AUC and the Cmax after the coadministration of 
naproxen. Finally, the concomitant administration of 
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tory assays that can be recommended to monitor rivar-
oxaban or any recommendations for dose adjustments 
based on observed test results. For instance, the 
thromboplastins used for PT clotting assays have dif-
fering sensitivities to factor Xa inhibitors, and the 
INR introduced to correct for differences in PT sen-
sitivity when monitoring the VKAs does not ade-
quately correct for differences in assay sensitivity to 
direct factor Xa inhibitors. Smith and Morissey 424 
evaluated the effects of fi ve commercial thrombo-
plastin reagents on sensitivity of the PT to rivaroxa-
ban and its correlation with the INR. PT ratios (ie, 
PT with drug/PT without drug) were measured using 
normal human plasma to which rivaroxaban 1  m g/mL 
was added in vitro. PT ratios varied from 2.25 to 7.32 
with the different thromboplastins; subsequent con-
version to an INR further exacerbated the observed 
differences in sensitivities to rivaroxaban between the 
various PT assays. 
 Recently, Samama et al 402 carried out a study that 
aimed to identify a clotting test suitable for moni-
toring rivaroxaban activity by evaluating the effects 
on a number of different assays of increasing the 
drug concentration in pooled citrated normal human 
platelet-poor plasma. There was a concentration-
dependent prolongation of the PT and aPTT, but the 
increases in clotting times varied depending on the 
thromboplastin reagent used. 402 The effect of rivar-
oxaban on the aPTT was weaker than that on the PT. 
Rivaroxaban also prolonged the thromboelastograph 
parameters. Standard methods for the HEPTEST and 
the prothrombinase-induced clotting time resulted 
in paradoxical responses. Tests used to measure anti-
factor Xa activity of the low-molecular-weight heparins 
showed dose-dependent effects but were associated 
with some degrees of variation. Finally, rivaroxaban 
also caused a dose-dependent increase of the diluted 
Russell viper venom ratio. Specifi c calibration of 
some of these tests may lead to the availability of an 
appropriate assay to monitor the pharmacodynamic 
effects of the drug. Neither the PT (expressed either 
in seconds or as a ratio) nor the aPTT should be used 
to monitor the anticoagulant effect of rivaroxaban. 
 3.6 Practical Issues Related to Initiation 
and Maintenance 
 Rivaroxaban is currently approved in many coun-
tries for the prevention of VTE in patients under-
going total hip replacement surgery and total knee 
replacement surgery based on the results of four 
phase 3 clinical trials. 393-396 For this indication, the 
approved dose is 10 mg once daily. Treatment should 
be started between 6 and 10 h after surgery, and the 
duration of treatment should vary from 2 weeks in 
patients undergoing total knee replacement surgery 
factor pathway, reduces the maximum concentration 
of generated thrombin, and decreases the endoge-
nous thrombin potential. 400 The effect on the initia-
tion and propagation phases of thrombin generation 
is greater than the effect on the decay phase, expressed 
by the endogenous thrombin potential. High concen-
trations of rivaroxaban are able to prevent thrombin 
generation almost completely, due to inhibition of 
factor Xa bound to the prothrombinase complex. 400 
The effect of rivaroxaban on platelet-induced throm-
bin generation in vivo was tested in a randomized, 
placebo-controlled, crossover study of 12 healthy male 
subjects aged 27 to 37 years. 397 The prothrombinase-
induced clotting time, a plasma clotting assay based 
on the activation of coagulation using factor Xa, 
phospholipids, and an enzyme that activates factor V, 
was prolonged dose dependently by rivaroxaban, 
with a maximum effect after 2 h. Thrombin genera-
tion in platelet-rich plasma was markedly reduced by 
rivaroxaban, with an 80% to 90% decrease (by 5-mg 
and 30-mg doses, respectively) of the peak collagen-
induced endogenous thrombin potential at 2 h. There 
was a close correlation between plasma concentra-
tion of rivaroxaban and its effects on factor Xa acti v-
ity inhibition, prothrombinase-induced clotting time 
prolongation, and endogenous thrombin potential 
reduction. 397 
 Rivaroxaban has no effects on platelet aggrega-
tion induced by collagen, adenosine diphosphate, or 
thrombin. 403,421,422 An indirect effect on platelet aggre-
gation induced by tissue factor, determined by the 
inhibition of thrombin generation, has been reported 
in defi brinated plasma. 423 
 In venous thrombosis models and in arteriovenous 
shunt models, rivaroxaban was shown to cause dose-
dependent reduction of thrombus formation, inhibi-
tion of factor Xa activity, and prolongation of the 
PT. 399 The antithrombotic effective doses of rivaroxa-
ban did not prolong bleeding time in animal bleeding 
models. 399 
 3.5 Monitoring Anticoagulant Intensity 
 The predictable pharmacologic profi le of rivaroxa-
ban allows the administration of the drug at fi xed 
doses without the need for routine laboratory moni-
toring or dose adjustments. However, there may 
be rare situations, as in the case of overdose or unex-
pected bleeding, assessment of compliance, evalu-
ation of drug interactions, or assessment of drug 
accumulation in renal or hepatic impairment, when 
the availability of a quantitative clotting assay might 
be valuable. Despite the predictable, dose-dependent 
effects of rivaroxaban on the PT and (to a lesser 
extent) the aPTT, and on tests measuring thrombin 
generation, there are currently no validated labora-
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ban was noninferior to warfarin in the prevention of 
ischemic stroke or systemic embolism, with a similar 
rate of major bleeding events but with fewer intracra-
nial and fatal bleeding events. 426 
 Other recently completed phase III trials include a 
study on the prevention of VTE in medical patients 
(Multicenter, Randomized, Parallel Group Effi cacy 
and Safety Study for the Prevention of VTE in Hospi-
talized Medically Ill Patients Comparing Rivaroxaban 
with Enoxaparin [MAGELLAN] study), in which 
rivaroxaban is administered at the same 10 mg once-
daily dose used in the Regulation of Coagulation in 
Major Orthopedic Surgery Reducing the Risk of DVT 
and PE (RECORD) program; and the EINSTEIN 
PE study, in which patients with hemodynamically 
stable PE are treated for the fi rst 3 weeks with a 
15 mg bid dose of rivaroxaban followed by a 20 mg 
once-daily dose. Finally, a phase III study in patients 
with acute coronary syndromes is assessing rivaroxa-
ban doses of 2.5 mg and 5.0 mg bid. 427 
 3.7 Adverse Events 
 3.7.1 Bleeding Events:  Data on the incidence of 
bleeding complications with the use of rivaroxaban 
are currently available from the results of phase II 
and phase III clinical trials only. As of yet, no pub-
lished phase IV studies or reports from clinical prac-
tice have been published. Reported rates must take 
into account the defi nition of bleeding used in each 
study, given the variability of defi nitions used among 
clinical trials assessing different compounds. 
 The reported rates of any bleeding with rivaroxa-
ban in the four phase III clinical trials carried out in 
patients undergoing total hip and total knee replace-
ment surgery range from 4.9% to 10.5% 393-396 and are 
comparable to the rates observed in patients treated 
with enoxaparin. Rates of major bleeding events vary 
from  , 0.1% to 0.7%, and the rates of clinically rele-
vant nonmajor bleeding events vary from 2.6% to 
3.3%, again with no statistically signifi cant differences 
between the rates observed in the rivaroxaban groups 
and the rates observed in the comparator groups 
(ie, the low-molecular-weight heparin enoxaparin 
in all studies). 393-396 A pooled analysis of the four 
RECORD studies reported that the concomitant use 
of nonsteroidal antiinfl ammatory drugs, aspirin, or 
other antiplatelet agents was not associated with an 
increased rate of bleeding events. 428 
 The rate of any bleeding event in patients with a 
previous episode of VTE treated with rivaroxaban 
20 mg once daily for 6 to 12 months after the ini-
tial standard course of anticoagulant therapy was 
23%; major bleeding and clinically relevant nonmajor 
bleeding occurred in 0.7% and 5.4% of patients, 
respectively. 425 
to 5 weeks in patients undergoing total hip replace-
ment surgery, although approved durations may 
vary among countries. Rivaroxaban is currently not 
approved for use in patients with severe renal failure 
and a creatinine clearance of  , 15 mL/min, in patients 
with hepatic disease associated with coagulopathy, 
and in patients receiving concomitant systemic 
treatment with azole-antimycotics or HIV protease 
inhibitors. 414 Rivaroxaban is also not approved for use 
in children or adolescents  , 18 years of age because 
of the absence of clinical data, in pregnant women 
because of the potential for reproductive toxicity 
(observed in animals) and the evidence that the 
drug passes the placenta, and during breast-feeding 
because the drug is secreted into milk. 414 
 Future additional indications are expected following 
the results of recently published clinical trials. In par-
ticular, more information on the long-term admin-
istration of rivaroxaban now originates from studies 
carried out in patients with VTE or AF in whom the 
drug was administered for a minimum of 6 months 
and up to a maximum of 40 months. 425,426 
 To date, the results of a phase III clinical trials 
assessing the use of rivaroxaban in the treatment 
of DVT have been published. In the EINSTEIN 
study,  . 3,400 patients with acute symptomatic prox-
imal DVT were allocated to rivaroxaban 15 mg bid 
for 3 weeks followed by 20 mg once daily or initial 
therapy with enoxaparin (1 mg/kg bid) and simulta-
neous warfarin administered to a target INR of 
2.0 to 3.0. 425 The primary outcome measure was 
symptomatic recurrent VTE, which occurred in 36 
rivaroxaban-treated patients and 51 low-molecular-
weight heparin/warfarin-treated patients (HR, 0.68; 
95% CI, 0.44-1.04;  P  , .0001 for noninferiority). 
Patients who had completed 6 to 12 months of anti-
coagulant treatment with either a VKA or rivaroxaban 
(if also enrolled in the acute-phase rivaroxaban treat-
ment study) after an acute episode of VTE were ran-
domized to receive rivaroxaban 20 mg once daily or 
matching placebo for additional 6 to 12 months. The 
study showed superior effi cacy of rivaroxaban over 
placebo in the prevention of recurrent venous throm-
boembolic events, a nonsignifi cant increase in major 
bleeding, and an increase in clinically relevant, non-
major bleeding events. 425 
 More recently, the results of the Rivaroxaban 
Once Daily Oral Direct Factor Xa inhibition Com-
pared with Vitamin K Antagonist for the Prevention 
of Stroke and Embolism Trial in Atrial Fibrillation 
(ROCKET) study comparing rivaroxaban 20 mg once 
daily (15 mg once daily if patients had a creatinine 
clearance between 30 and 49 mL/min) with warfarin 
in patients with AF and at least two additional risk 
factors for embolic events were published. In this 
randomized, double-blind, controlled trial, rivaroxa-
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 Conclusion 
 Over the last decades, a large amount of research 
has been addressed to improve the understanding 
of the mechanisms of warfarin, acenocoumarol, and 
phenprocoumon and to improve the management of 
patients treated with these VKAs. Several studies 
have in particular identifi ed some genetic factors 
associated with the individual responses to VKAs and 
several drugs, foods, and environmental factors that 
can interact with these compounds. Several induction 
and maintenance strategies have been compared, 
and management studies have evaluated different 
approaches for the monitoring of patients on VKAs, 
including AMS and AC, computer programs, and 
POC for INR testing. The results of all such studies 
have greatly contributed to improve the effi cacy and 
safety of oral anticoagulant therapy and to increase 
the number of patients who can be deemed eligible 
for such treatment. Finally, a number of trials have 
also addressed the management of patients on VKA 
treatment who are at increased risk of bleeding or are 
actively bleeding, and a number of therapeutic strat-
egies have been proposed, although additional research 
may be warranted in particular to further improve 
the management of the bleeding patient. 
 The new oral anticoagulant drugs have the poten-
tial to overcome several drawbacks of the VKAs. 
These drugs can be administered at fi xed doses and 
do not require laboratory monitoring, thus offering a 
clear advantage over the VKAs. It is hoped that new 
studies will provide us with further information on 
the role of specifi c laboratory tests for the monitoring 
of the activity of these new classes of drugs, when 
requested, and on the optimal management of drug-
related adverse events. 
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 3.7.2 Nonhemorrhagic Adverse Events:  None of 
the four phase III clinical trials found evidence of 
drug-associated liver toxicity in patients treated with 
rivaroxaban for up to 5 weeks. 393-396 Overall, the pro-
portion of patients with elevated liver enzymes was 
low in all studies and was similar between rivaroxa-
ban and enoxaparin. The incidence of cardiovascular 
events was low while on treatment with rivaroxaban, 
ranging between 0.1% and 0.7%, and was similar to 
that seen with enoxaparin. Drug-related adverse 
events occurred in 12% to 20% of patients in the four 
RECORD trials; these rates were similar to those 
observed with enoxaparin. The most frequent adverse 
events were nausea, vomiting, and constipation. 
 3.8 Reversal 
 There is currently no specifi c antidote available to 
antagonize the effects of rivaroxaban. In case of over-
dose, the use of activated charcoal to reduce absorp-
tion is suggested. 414 Because of the high plasma 
protein binding, rivaroxaban is unlikely to be dialyz-
able. In case of active bleeding, possible strategies 
currently include discontinuation of treatment and 
administration of blood products or component trans-
fusion if required to treat an identifi ed defi ciency. 414 
However, there is currently no direct evidence in 
humans to support the effi cacy of blood product trans-
fusion or other interventions in improving hemostasis 
when patients have received rivaroxaban. Recently, 
Perzborn et al 429 reported the results of a study car-
ried out in rats treated with high-dose rivaroxaban, 
which aimed to assess the effi cacy of prothrombin 
complex concentrate. After determination of baseline 
mesenteric bleeding time, rats were initially treated 
with IV rivaroxaban and subsequently received four-
factor prothrombin complex concentrates at 25 U/kg 
or 50 U/kg. Prolongation of the bleeding time was 
almost completely abrogated by higher dose of 
prothrombin complex concentrates, whereas the 
lower dose was ineffective. The use of recombi-
nant factor VIIa is also suggested in the presence of 
life-threatening bleeding based on some preclinical 
data. 414 A reconstructed recombinant factor Xa has 
been recently proposed as a potential antidote for 
factor Xa inhibitors. 430 This is a catalytically inactive 
factor Xa that has no procoagulant or anticoagulant 
activity and does not interfere with the prothrombi-
nase complex but maintains high affi nity for factor Xa 
inhibitors. In plasma, the addition of the antidote 
dose-dependently reversed factor Xa inhibition as 
measured by anti-factor Xa units, tissue factor-initiated 
thrombin generation, and clotting assays. In vivo, 
the antidote completely reversed PT prolongation 
induced by intravenous infusion of rivaroxaban 
in rats. 
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